



Characterization of a Human Point Mutation of VGLUT3 (p.A211V) in the Rodent Brain Suggests a Nonuniform Distribution of the Transporter in Synaptic Vesicles

Lauriane Ramet, Johannes Zimmermann, Tiphaine Bersot, Odile Poirel, Stéphanie de Gois, Katlin Silm, Diana Yae Sakae, Nina Mansouri-Guilani, Marie-Josée Bourque, Louis-Eric Trudeau, et al.

► To cite this version:

Lauriane Ramet, Johannes Zimmermann, Tiphaine Bersot, Odile Poirel, Stéphanie de Gois, et al.. Characterization of a Human Point Mutation of VGLUT3 (p.A211V) in the Rodent Brain Suggests a Nonuniform Distribution of the Transporter in Synaptic Vesicles. *Journal of Neuroscience*, 2017, 37 (15), pp.4181-4199. 10.1523/JNEUROSCI.0282-16.2017 . hal-01510648

HAL Id: hal-01510648

<https://hal.sorbonne-universite.fr/hal-01510648>

Submitted on 19 Apr 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title:

Characterization of a human point mutation of VGLUT3 (p.A211V) in the rodent brain suggests a non-uniform distribution of the transporter in synaptic vesicles

Abbreviated title:

VGLUT3 p.A211V mutation

Lauriane Ramet¹, Johannes Zimmermann², Tiphaine Bersot¹, Odile Poirel¹, Stéphanie De Gois¹, Katlin Silm¹, Diana Yae Sakae¹, Nina Mansouri-Guilani¹, Marie-Josée Bourque³, Louis-Eric Trudeau³, Nicolas Pietrancosta⁴, Stéphanie Daumas¹, Véronique Bernard¹, Christian Rosenmund², Salah El Mestikawy^{1,5*}

¹ Centre National de la Recherche Scientifique (CNRS) UMR 8246, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR-S 1130, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris-Seine (IBPS), UM119 Neuroscience Paris Seine, F-75005, Paris, France.

² Neurocure NWFZ, Charite Universitaetsmedizin, 10117 Berlin, Germany

³ Department of Pharmacology, Faculty of Medicine, GRSNC, Université de Montréal, QC, Canada; Department of Neurosciences, Faculty of Medicine, GRSNC, Université de Montréal, QC, Canada

⁴ CNRS UMR-8601, Université Paris Descartes, CICB, Team Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, 45 rue des Saint-Pères, 75006 Paris, France.

⁵ Douglas Hospital Research Center, Department of Psychiatry, McGill University, 6875 boulevard Lasalle Verdun, QC, Canada

*Correspondence should be addressed to Salah El Mestikawy, Inserm U 1130, CNRS UMR 8246, Université Pierre et Marie Curie UM 119, 7 quai Saint Bernard, 75005, Paris, France.

E-mail: salah.el_mestikawy@upmc.fr

Number of pages: 47

Number of: Figures: 10
 Tables: 3
 3D models: 0

Number of words for: Abstract: 244
 Statement: 114
 Introduction: 652
 Discussion: 2139 (1500)

Conflict of Interests: The authors declare no competing financial interests.

Acknowledgements

This research was supported by funds from the *Fondation pour la Recherche médicale* (Équipe FRM DEQ20130326486), the *Agence Nationale pour la Recherche* (ANR), the *Fédération pour la Recherche sur le Cerveau*, Labex (Bio-Psy Laboratory of Excellence), INSERM, CNRS and UPMC.

LR received a PhD fellowship from the *Ministère de l'enseignement supérieur et de la recherche* and from the *Fondation pour la Recherche médicale* (FDT20140930909).

We thank Géraldine Toutirais from the *Service de Microscopie Electronique of the Institut de Biologie Paris-Seine* (Université Pierre et Marie Curie, Paris). We thank Valérie Nicolas from the *Plateforme d'imagerie cellulaire of the Institut Paris Saclay d'Innovation Thérapeutique* (UMS IPSIT Université Paris-Sud – US 31 INSERM – UMS 3679 CNRS, Châtenay-Malabry) for assistance with STED microscopy. We thank Christoph Biesemann for the lentivirus constructs, Stéphanie Pons and Martine Soudant as well as l'*École des Neurosciences de Paris* (ENP) ("Network for Viral Transfer") for producing the lentiviruses.

Abstract

The atypical vesicular glutamate transporter type 3 (VGLUT3) is expressed by sub-populations of neurons using acetylcholine, GABA or serotonin as neurotransmitters. In addition, VGLUT3 is expressed in the inner hair cells of the auditory system. A mutation (p.A211V) in the gene that encodes VGLUT3 is responsible for progressive deafness in two unrelated families. In this study, we investigated the consequences of the p.A211V mutation in cell cultures and in the central nervous system (CNS) of a mutant mouse. The mutation substantially decreased VGLUT3 expression (-70%). We measured VGLUT3-p.A211V activity by vesicular uptake in BON cells, electrophysiological recording of isolated neurons and its ability to stimulate serotonergic accumulation in cortical synaptic vesicles. Despite a marked loss of expression, the activity of the mutated isoform was only minimally altered. Furthermore, mutant mice displayed none of the behavioral alterations that have previously been reported in VGLUT3 knockout mice. Finally, we used stimulated emission depletion microscopy (STED) to analyze how the mutation altered VGLUT3 distribution within the terminals of mice expressing the mutated isoform. The mutation appeared to reduce the expression of the VGLUT3 transporter by simultaneously decreasing the number of VGLUT3-positive synaptic vesicles and the amount of VGLUT3 per synapses. These observations suggested that VGLUT3 global activity is not linearly correlated with VGLUT3 expression. Furthermore, our data unraveled a non-uniform distribution of VGLUT3 in synaptic vesicles. Identifying the mechanisms responsible for this complex vesicular sorting will be critical to understand VGLUT's involvement in normal and pathological conditions.

Significance Statement

VGLUT3 is an atypical member of the vesicular glutamate transporter family. A point mutation of VGLUT3 (VGLUT3-p.A211V) responsible for a progressive loss of hearing has been identified in humans. We observed that this mutation dramatically reduces VGLUT3 expression in terminals (approximately 70%) without altering its function. Furthermore, using stimulated emission depletion (STED) microscopy, we found that reducing the expression levels of VGLUT3 diminished the number of VGLUT3-positive vesicles at synapses. These unexpected findings challenge the vision of a uniform distribution of synaptic vesicles at synapses. Therefore, the overall activity of VGLUT3 is not proportional to the level of VGLUT3 expression. These data will be key in interpreting the role of VGLUTs in human pathologies.

INTRODUCTION

Glutamate accumulation within synaptic vesicles (SVs) is facilitated by the vesicular glutamate transporters VGLUT1, VGLUT2 and VGLUT3 (for review see (El Mestikawy et al., 2011)). VGLUTs are crucial anatomical and functional markers of glutamatergic transmission. The amount of glutamate that is packaged into SVs and the amount of glutamate that is released are believed to be proportional to the density of VGLUT expression (Daniels et al., 2004; Wilson et al., 2005; Daniels et al., 2006; Moechars et al., 2006; Daniels et al., 2011). In addition to glutamate vesicular packaging, additional roles for the VGLUTs have recently been revealed. For example, VGLUTs influence the mobility of SVs in the axon and their stability in the synapse, as well as the intrinsic release probability of glutamatergic vesicles (Weston et al., 2011; Siksou et al., 2013; Herman et al., 2014). The VGLUTs are structurally and functionally similar but are anatomically segregated. VGLUT1-2 are used by cortical and subcortical excitatory terminals, respectively (Bellocchio et al., 2000; Takamori et al., 2000; Fremeau et al., 2001; Herzog et al., 2001; Takamori et al., 2001; Varoqui et al., 2002). In contrast, VGLUT3 is localized in small populations of neurons using neurotransmitters other than glutamate, such as cholinergic interneurons in the striatum, subsets of GABAergic interneurons in the hippocampus and cortex and serotonergic neurons in the dorsal and median raphe nuclei (Fremeau et al., 2002; Gras et al., 2002; Schafer et al., 2002; Takamori et al., 2002; Herzog et al., 2004). At the cellular level, VGLUTs are present in terminals. However, unlike VGLUT1 and VGLUT2, VGLUT3 is also observed in somato-dendritic compartments (Herzog et al., 2004). VGLUT3 facilitates vesicular accumulation and release of acetylcholine, serotonin and GABA via a mechanism called “vesicular synergy” (Gras et al., 2008; Amilhon et al., 2010; Zander et al., 2010). VGLUT3 confers on “non-glutamatergic” cells the ability to release glutamate (Varga et al., 2009; Higley et al., 2011; Nelson et al., 2014). Mice that no longer express VGLUT3 (VGLUT3^{-/-}) display hypersensitivity to pain, increased anxiety and increased sensitivity to cocaine (Gras et al., 2008; Seal et al., 2009; Amilhon et

al., 2010; Peirs et al., 2015; Sakae et al., 2015). Interestingly, heterozygous mice display no specific altered phenotype.

VGLUT3 is expressed by sensory inner hair cells in the auditory system. Therefore, VGLUT3^{-/-} mice are profoundly deaf (Ruel et al., 2008; Seal et al., 2008). In humans, the p.A211V mutation of the gene that encodes VGLUT3 (*Slc17a8*) is responsible for a type of progressive deafness, DFNA25 (Ruel et al., 2008). This observation was the first evidence of an association between human pathology and a VGLUT mutation.

The mutated alanine is part of a peptide sequence that is highly conserved among the VGLUTs and their orthologs. The A211 alanine in human VGLUTs corresponds to position 224 in the mouse VGLUT3 sequence (A224). In this report, we generated a mutant mouse carrying the p.A211V mutation (VGLUT3^{A224V/A224V}) and investigated its effects on the CNS. The VGLUT3^{A224V/A224V} mice present the same progressive loss of hearing reported in humans ((Ruel et al., 2008), Miot et al., manuscript in preparation).

In the CNS, we observed that the amount of mutated VGLUT3-p.A224V protein was dramatically reduced in nerve endings (~70%). Moreover, VGLUT3-dependent vesicular accumulation and synaptic release of glutamate were only minimally altered in VGLUT3^{A224V/A224V} mice. Increased anxiety as well as increased basal or cocaine-induced locomotor activity have been observed in VGLUT3^{-/-} mice. Despite substantial loss of VGLUT3, VGLUT3^{A224V/A224V} mice displayed no such behavioral alterations. Therefore, the molecular, cellular and behavioral functions of VGLUT3 are as efficiently fulfilled with 100% or with 30% expression of the transporter. This observation suggests that VGLUT3 global activity is not linearly correlated with the amounts of VGLUT3 present in terminals.

Finally, with stimulated emission depletion (STED) microscopy, we observed a decrease of VGLUT3-p.A224V-positive vesicles in the terminals. Together, these observations establish that the p.A211V mutation has complex effects on VGLUT3 expression and targeting.

MATERIALS AND METHODS

Animals

Animal care and experiments were conducted in accordance with the European Communities Council Directive for the Care and the Use of Laboratory Animals (86/809/EEC) and in compliance with the *Ministère de l'Agriculture et de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale* (authorization # 01482.01 from ethics committee Darwin #5). All efforts were made to minimize the number of animals used in the course of the study and to ensure their well-being. The animals were housed in a temperature-controlled room (21± 2°C) with free access to water and food under a light/dark cycle of 12 h (light 7:30 - 19:30).

Construction, genotyping and breeding of VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice

The p.A211V mutation has been described in two unrelated human families (Ruel et al., 2008). The alanine at position 211 of human VGLUT3 is part of a KWAPPLER motif and is highly conserved in all three VGLUTs among different species (Ruel et al., 2008). In mouse VGLUT1 and VGLUT3, this alanine is at positions 198 and 224, respectively (Fig. 1A). A mouse line expressing the p.A224V mutation was generated at Phenomin - iCS (Phenomin-Institut Clinique de la Souris-, Illkirch, France; <http://www.phenomin.fr/>) and was named VGLUT3^{A224V/A224V}. A point mutation was introduced in exon 5 of the mouse *Slc17a8* gene: a GCG (coding for an alanine) was exchanged for a GTG (coding for a valine) (Fig. 1B). Mice were genotyped by PCR analysis of tail DNA with the following PCR primers: (p1) 5'-CGGAGGGGAAGCCAGGAAAGGG-3' and (p2) 5'-GACAGCTCAGTGAGCTGTAGACCCAG-3' for the WT and the mutated allele, yielding bands of 219 and 306 bp, respectively (Fig. 1C). Mice used in the study were aged 10 days to 12 months. They were obtained by crossing heterozygous VGLUT3^{A224V/+} (C57BL/6N genetic background) or VGLUT3^{+/-} (VGLUT3^{-/-}, (Sakae et al., 2015)) mice with VGLUT3^{A224V/+} (C57BL/6N) mice (Table I). Breeding provided

mice expressing either: i) 2 copies of the VGLUT3 WT allele (VGLUT3^{+/+} or WT), ii) one copy of mutated and one copy of VGLUT3 WT allele (VGLUT3^{A224V/+}), iii) 2 copies of mutated alleles (VGLUT3^{A224V/A224V}) or iv) only one copy of mutated alleles (VGLUT3^{A224V/-}).

Male littermates were used for the behavioral analysis, and females or males were used for the anatomical and biochemical experiments. The animals were randomly allocated to the experimental groups. Whenever possible, investigators were blinded to the genotypes during the experimental procedures. Animals were excluded from the experimental data analysis only when their results were detected as outliers using Grubb's test (GraphPad Prism software, La Jolla, CA USA).

Behavioral experiments

Spontaneous locomotor activity: Basal locomotor activity was assessed as previously described (Gras et al., 2008). Mice were placed individually in activity boxes (20 x 15 x 25 cm), where their horizontal and vertical activities were measured by photocell beams located across the long axis, 15 mm (horizontal activity) and 30 mm (vertical activity) above the floor. Each box was connected by an interface to a computer (Imetronic). Spontaneous locomotor activity was measured in 15 min intervals over five hours between 18:30 and 23:30 p.m.

Open field (OF): The open field test was performed in a white Perspex arena (43 x 43 x 26 cm) located in a 10 lux illuminated room, as previously reported (Amilhon et al., 2010). The virtual central compartment square represented 1/3 of the total arena. Mice were introduced into the central area and allowed to freely explore the open field for 360 sec. The durations, frequencies and time courses of various behaviors (exploration, walking, rearing, stretching and grooming) were measured in different regions of the open field (central vs periphery zone). The time and number of entries in the center of the open field were evaluated as an index of an anxiety-related response.

Elevated plus maze (EPM): EPM was used to measure unconditioned anxiety-like behavior (Amilhon et al., 2010). The EPM, which consisted of two open arms, two enclosed arms and a central platform elevated 38.5 cm above the ground, was placed into 10 lux ambient light.

After being allowed one hour of habituation in the testing room, the animals were placed in the central area, facing one of the closed arms, and were tested for 360 sec. The total time spent in each compartment (open vs closed arms) was recorded by video tracking (Viewpoint).

Cocaine-induced locomotor activity: Cocaine-induced locomotor activity was measured in a cyclotron, which consisted of a circular corridor with four infrared beams placed at 90° angles (Imetronic). Activity was counted as the consecutive interruption of two adjacent infrared beams (1/4 of a tour). To assess acute cocaine-induced locomotion, the animals were i) placed in the cyclotron for four hours for habituation, ii) injected with saline (NaCl 0.9%) and placed back in the cyclotron for 60 min and iii) injected with cocaine (10 mg/kg, intraperitoneal (i.p)). Locomotion was recorded for 95 min following cocaine injection.

Neuronal microculture and electrophysiological recording of autapses

Hippocampi were harvested at postnatal day 0 (P0) to P1 from VGLUT1^{-/-} mice of either sex (Wojcik et al., 2004). Neurons were plated on island cultures at a density of 2000-3000 neurons per 35 mm dish. Recordings were performed from 14 to 18 DIV. VGLUT1^{-/-} autaptic neurons were infected with either VGLUT3 or VGLUT3-p.A211V lentiviral vectors (respectively: 10 and 40 ng p24 per well). In order to normalize expression levels and to compare electrophysiological activity of the 2 isoforms, five times more VGLUT3-p.A211V than WT expressing viral particles were used to rescue VGLUT1^{-/-} hippocampal neurons.

The standard extracellular solution contained the following (in mM): 140 NaCl, 2.4 KCl, 10 HEPES, 10 glucose, 4 MgCl₂, and 2 CaCl₂, pH 7.3. The internal solution contained the following (in mM): 135 KCl, 18 HEPES, 1 EGTA, 4.6 MgCl₂, 4 ATP, 0.3 GTP, 15 creatine phosphate, and 20 U/ml phosphocreatine kinase. Excitatory postsynaptic currents (EPSCs) were evoked by 2 ms of depolarization at 0 mV, resulting in an unclamped action potential. Readily releasable vesicle pool (RRP) size was assessed by pulsed (5 s) application of hypertonic sucrose solution (500 mM sucrose added to extracellular solution) and by integrating the transient inward current component. Vesicular release probability was

computed by dividing the EPSC charge by the RRP charge. Current traces were analyzed using Axograph X (Axograph), Excel (Microsoft) and Prism (GraphPad). The mEPSCs were detected with a template function (Axograph; template: rise, 0.5 ms; decay, 3 ms; criteria range: rise, 0.15-1.5 m; decay, 0.5-5 ms).

In situ hybridization labeling of VGLUT3 mRNA

Regional *in situ* hybridization was performed as previously described (Gras et al., 2008; Amilhon et al., 2010; Vigneault et al., 2015). Mouse brains were rapidly dissected and frozen in isopentane at -30°C. Coronal brain sections (12 μ m) were cut with a cryostat (Leica Biosystems) at -20°C, thaw-mounted on glass slides, fixed in 4% formaldehyde, washed with PBS, dehydrated in 50% and 70% ethanol and air-dried. The sections were incubated with a mixture of 9 antisense oligonucleotides specific for mouse VGLUT3 (5'-TCAGAAGCTGTCATCCTCTCTCAACTCCAG-3', 5'-GGCATCTTCCTCTTCATTGGTCCCATCGAT-3', 5'-CCCTTCTCCTCTCGATCCAGAATCAACAAA-3', 5'-ACTGCGCTTGCCCTGGAGGAACACTTGAAA-3', 5'-GCCGTAATGCACCCTCGCCGCAGAAGGGATAAAC-3', 5'-GGGCAGCCAAGCTCAGAATGAGCACAGCCTGTATCC-3', 5'-AGTCACAGATGTACCGCTTGGGGATGCCGCAGCAG-3', 5'-AGCCAGTTGTCCTCCGATGGGCACCACGATTGTC-3' and 5'-CCACAATGGCCACTCCAAGGTTGCACCGAATCCC-3'). These oligonucleotides were labeled with [³⁵S]-dATP (Perkin Elmer) to a specific activity of 5 x 10⁸ dpm/ μ g using terminal deoxynucleotidyl transferase (Promega). Sections were incubated for 18 h at 42°C, washed and exposed to a BAS-SR Fujifilm Imaging Plate for seven days. The plates were scanned with a Fuji Bioimaging Analyzer BAS-5000. Densitometry measurements were performed with MCID™ analysis software. Densitometric analysis of 4-6 sections for each region was averaged per mouse (8 mice per genotype).

Immunoautoradiographic labeling of VGLUT3

Immunoautoradiography experiments were performed on fresh frozen mouse brain sections (12 μm) as previously described (Amilhon et al., 2010; Vigneault et al., 2015). Brain slices were incubated with VGLUT3 rabbit polyclonal antiserum (1:20,000, Synaptic Systems) and then with anti-rabbit [^{125}I]-IgG (Perkin Elmer). The sections were then washed in PBS, rapidly rinsed in water, dried and exposed to X-ray films (Biomax MR, Kodak) for five days. Standard radioactive microscopes were exposed to each film to ensure that labeling densities were in the linear range. Densitometry measurements were performed with MCIDTM analysis software on 4-6 sections for each region per mouse (8 mice per genotype).

Immunofluorescence

Immunofluorescence experiments were performed on BON cells, hippocampal primary neurons and brain slices, as previously described (Herzog et al., 2001; Gras et al., 2002; Herzog et al., 2011). Cells or brain sections were incubated with anti-human VGLUT3 rabbit polyclonal antiserum (1:1000, (Vigneault et al., 2015))(Gras et al., 2002), anti-rodent VGLUT3 rabbit polyclonal antiserum (1:2000, Synaptic Systems), anti-rodent VGLUT1 rabbit polyclonal antiserum (1:2000, (Herzog et al., 2001)), anti-rodent MAP2 mouse monoclonal antiserum (1:1000, Sigma), anti-rodent bassoon mouse monoclonal antiserum (1:2000, Abcam) or PSD95 mouse monoclonal antiserum (1:2000, Abcam). Immunolabeling was detected with anti-rabbit or anti-mouse secondary antisera coupled to Alexa Fluor 555 or Alexa Fluor 488 (1:2000, Invitrogen). Nuclei were labeled using DAPI (1:5000, Sigma). The cells and sections were observed with a fluorescence microscope equipped with an Apotome module (Zeiss, Axiovert 200 M) or a confocal Laser Scanning Microscope (Leica TCS SP5, Leica Microsystems). Fluorescence intensity in the synaptic boutons of hippocampal neuronal cultures was quantified using the MacBiophotonics plugins package for ImageJ software. In the brain slices, semi-quantification of VGLUT3 in the soma and terminals was performed with ImageJ software (Macbiophotonics plugins). The contour of neuronal soma or brain areas containing terminals were delineated manually and the integrated intensity within

these region of interest (ROI) were measured using the ROI manager of the ImageJ software.

Electron microscopy immunogold detection of VGLUT3

Electron microscopy experiments were performed on WT and VGLUT3^{A224V/A224V} mice, as previously described (Bernard et al., 1999; Herzog et al., 2001). Briefly, the animals were deeply anesthetized and perfused transcardially with a mixture of 2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and 0.2% glutaraldehyde. Their brains were dissected, fixed overnight in 2% paraformaldehyde and stored in PBS until use. Sections (70 μ m) from the midbrain, including the striatum, were cut on a vibrating microtome (Leica Biosystems, VT1000S). Sections were successively incubated in anti-rodent VGLUT3 rabbit polyclonal antiserum (1:2000, Synaptic System), in goat anti-rabbit coupled to biotin (Vector laboratories) and in streptavidin coupled to gold particles (0.8 nm in diameter; Nanoprobes; 1:100 in PBS/BSA-C). The signal of the gold immunoparticles was increased using a silver enhancement kit (HQ silver; Nanoprobes) for 2 min at RT in the dark. Finally, after treatment with 1% osmium, dehydration and embedding in resin, ultrathin sections were cut, stained with lead citrate and examined in a transmission electron microscope (EM 912 OMEGA, ZEISS) equipped with a LaB6 filament at 80kV. Images were captured with a digital camera (SS-CCD, 2kx2k, Veleta).

VGLUT3 immuno-detection by STED microscopy

STED microscopy experiments were performed on WT, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V}, VGLUT3^{A224V/-} and VGLUT3^{-/-} mice. Briefly, the animals were deeply anesthetized and perfused transcardially with paraformaldehyde (2%). Their brains were dissected, fixed overnight in 2% paraformaldehyde and stored in PBS until use. Sections (70 μ m) from the midbrain, including the striatum, were cut on a vibrating microtome (Leica, VT1000S). VGLUT3 was detected in axonal varicosities in the mouse caudate putamen. To ensure that VGLUT3 was detected in varicosities, synaptophysin I, a synaptic vesicular protein, was co-

detected with VGLUT3. Sections were successively incubated in a mixture of anti-rodent VGLUT3 rabbit polyclonal antiserum (1:2000, Synaptic System) and anti-synaptophysin I mouse antiserum (1:2000, Synaptic System), in anti-mouse biotinylated secondary antibody (1:100, Vector Laboratories), and in a mixture of Streptavidin (1:100, BD Horizon™ V500, BD Biosciences) and Oregon Green 488 goat anti-rabbit IgG (Thermo Fisher Scientific) and mounted in ProLong Gold (Thermo Fisher Scientific).

Sections were observed using a SP8 gated-STED microscope (Leica Microsystems) equipped with a 592 nm depletion laser. BD Horizon™ V500 and Oregon Green 488 were excited at 470 nm and 514 nm, respectively. All acquisitions were performed using the same excitation laser power (50%). Alternatively, we compared the effect of increased laser power on the number of spots (50, 75, 100%). Images were submitted to deconvolution (Huygens software, Scientific Volume Imaging), which permits the recovery of objects that are degraded by blurring and noise. Finally, the images were analyzed using ImageJ and Adobe Photoshop. The number of VGLUT3-positive puncta per varicosity surface was quantified in each genotype (80, 76, 76, 90, 105 varicosities per animals were quantified in 6 WT, 6 VGLUT3^{A224V/+}, 6 VGLUT3^{A224V/A224V}, 6 VGLUT3^{A224V/-} and 5 VGLUT3^{-/-} mice, respectively).

Fluorescence recovery after photobleaching (FRAP)

FRAP experiments were performed to compare the mobility of VGLUT3-p.A211V with that of wild-type VGLUT3 at synapses. Primary culture of hippocampal neurons (as described below) were infected 48 h after plating with either VGLUT3 or VGLUT3-p.A211V lentiviral vectors (respectively: 10 and 40 ng p24 per well). In order to normalize expression levels of the 2 isoforms, five times more VGLUT3-p.A211V than WT expressing viral particles were used to infect hippocampal primary neurons. Experiments were performed as previously described (Herzog et al., 2011) using a SP5 Laser Scanning Microscope (Leica) with a 63X/1.32 numerical aperture oil-immersion objective and a thermal incubator set to 37°C surrounding the setup (Leica Microsystems). The pinhole was opened to 2.5 Airy units to enhance signal detection. A bleaching protocol was used to prevent spontaneous recovery of

345 venus fluorescence, as previously reported (McAnaney et al., 2005). Fluorescence recovery
346 was monitored every 30 s during the first 5 min and then every 5 min for the next 70 min for
347 FRAP and every 5 s for 10 min for Fast FRAP. The entire FRAP and Fast FRAP procedures
348 were automated using SP5 live data mode software. Image processing was automated using
349 ImageJ macro commands. Integrated fluorescence intensities were extracted from six
350 bleached and eight control boutons, as well as one background area. The background signal
351 was subtracted.

353 *BON cell culture and transfection*

354 Human carcinoid BON cells were maintained in 1:1 DMEM/F-12 medium supplemented with
355 10% fetal bovine serum (PAA Laboratories, GE Healthcare Life Sciences), 100 units/ml
356 penicillin and 100 μ g/ml streptomycin (Life Technologies) at 37°C in a humidified 5% CO₂
357 incubator as previously described (Herzog et al., 2001; Gras et al., 2002). BON cells were
358 transfected using Lipofectamine 2000 (Thermo Fisher Scientific) according to the
359 manufacturer's instructions with the expression vector pcDNA3 (Invitrogen) containing the
360 sequence coding for human VGLUT3 or VGLUT3-p.A211V coupled to green fluorescent
361 protein (GFP) reporter (pcDNA3-VGLUT3-IRES-GFP or -VGLUT3-p.A211V-IRES-GFP).
362 Stable clones were selected using G418 antibiotics (Merck, Millipore), and flow cytometry
363 was used to select GFP- and VGLUT3-positive cells. Stable clones expressing VGLUT3 or
364 VGLUT3-p.A211V were maintained in culture medium containing G418 (0.6 mg/ml).

366 *Hippocampal neuronal culture*

367 For immunofluorescence experiments, hippocampal cell cultures were prepared from
368 newborn P0-P2 (P0 being the day of birth) C57BL/6 pups of either sex as previously
369 described (Fasano et al., 2008). After seven days in culture, neurons were transfected with
370 linearized plasmid pcDNA3-VGLUT3-IRES-GFP or pcDNA3-VGLUT3-p.A211V-IRES-GFP
371 with lipofectamine 2000 (Thermo Fisher Scientific, 1 μ g of DNA for 1 μ l of lipofectamine). At 9
372 day *in vitro* (DIV), neurons were fixed and immunofluorescence experiments were performed.

For Fluorescence recovery after photobleaching (FRAP) experiments, hippocampal cell cultures were prepared as previously described (Siksou et al., 2013). After 2 days in culture, neurons were infected with lentiviral vectors containing either VGLUT3-venus or VGLUT3-p.A211V-venus inserts under the control of the synapsin promoter (respectively: 10 and 40 ng p24 per well). Viral particles expressing VGLUT3-venus or VGLUT3-p.A211V-venus were diluted 1:1000 in neurobasal medium (Life Technologies) containing Glutamax (Thermo Fisher Scientific), B27 and penicillin/streptomycin (Sigma-Aldrich). The diluted virus solutions (50 μ l at and 300 μ l for VGLUT3-venus and VGLUT3-p.A211V-venus expressing lentivirus, respectively) were incubated for 15 days with the primary neuronal cultures. FRAP imaging of live dissociated neuron cultures was performed at 17 DIV.

Mutagenesis and construction of VGLUT3-p.A211V and VGLUT1-p.A198V

To introduce a point mutation in the WT alleles, we used the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) and a set of complementary primers as previously described (De Gois et al., 2015). All clones were sequenced in both directions, and the plasmids were purified using a Plasmid Maxi Kit (Qiagen) before use.

Vesicular glutamate uptake assay with vesicles from stable BON clones

Synaptic vesicle preparations from the BON cells and [3 H]L-glutamate uptake assays were performed as previously described (Herzog et al., 2001; Gras et al., 2002). Transport activity was triggered by the addition of 20 μ l of vesicles (200 μ g of protein) to 180 μ l of uptake buffer containing ATP (2 mM, Sigma-Aldrich), L-glutamate (40 μ M pH 7.4, Sigma-Aldrich) and [3 H]L-glutamate (6 μ Ci, Perkin Elmer) with or without carbonyl cyanide m-chlorophenylhydrazone (CCCP, 50 μ M, Sigma-Aldrich). After 10 min at 37°C, the uptake assays were terminated by dilution with 3 ml of ice-cold 0.15 M KCl, rapid filtration through a 0.45 μ m pore size membrane filter (MF, Millipore), and three washes with 3 ml of ice-cold 0.15 M KCl. The radioactivity retained on the filters was measured by scintillation counting.

Each uptake measurement was performed in triplicate. All experiments were performed independently three times on three independent BON-VGLUT3 clones.

Vesicular [³H]5-HT uptake assay in mouse brain synaptic vesicles

Synaptic vesicle isolation from mouse cortex and uptake assays of [³H]5-HT were performed as previously described (Amilhon et al., 2010). Transport reactions were initiated by adding 10 μ l of cortical synaptic vesicles (25 μ g of protein) to 90 μ l of uptake buffer containing ATP (2 mM, Sigma-Aldrich) and [³H]5-HT (0.55 μ Ci, 50 nM, Perkin Elmer) with or without 2 μ M reserpine (Sigma-Aldrich) or L-glutamate (10 mM, Sigma-Aldrich). After 10 min at 37°C, vesicular uptake was stopped by dilution in 3 ml of ice-cold 0.15 M KCl, rapid filtration through mixed cellulose esters filters (MF, Millipore), and three washes with 3 ml of ice-cold 0.15 M KCL. Radioactivity retained on the filters was measured by scintillation counting. Each determination was performed in triplicate and independent experiments were performed seven times using different synaptic vesicle preparations.

Western blotting

Western blot experiments were conducted on BON cell extracts or on homogenates from different brain regions (cortex, striatum, hippocampus), as previously described (Gras et al., 2008; Vigneault et al., 2015). Nitrocellulose membranes (0.4 μ m pore size, Invitrogen) were incubated overnight with anti-human VGLUT3 rabbit polyclonal antiserum (1:1000, (Vigneault et al., 2015)), anti-rodent VGLUT3 rabbit polyclonal antiserum (1:2000, Synaptic Systems) or anti-rodent VGLUT1 rabbit polyclonal antiserum (1:5000, (Herzog et al., 2001)) and then with IRDye 800 conjugated secondary antibodies (1:5000, Invitrogen). Alpha-tubulin was used as loading control (mouse monoclonal antiserum, 1:20,000, Sigma-Aldrich) detected with IRDye 700 conjugated secondary antibodies (1:5000, Invitrogen). The membranes were scanned using an Odyssey infrared imaging system (LI-COR). Integrated intensity was measured for each band and averaged for 5-7 samples.

Quantitative reverse transcription-PCR analysis

The expression of VGLUT3 transcript in stable BON cells was estimated by quantitative reverse transcription PCR (RT-PCR), as previously described (Gras et al., 2002). Nucleic acids were extracted from 65×10^4 BON cells (RNAeasy Mini Kit, Qiagen). Reverse transcription was performed with a SuperScript® Reverse Transcriptase Kit (Life Technologies) using 2 μ g of nucleic-acid extract. cDNA amplification was performed with Taq™ DNA polymerase (Sigma-Aldrich), and the following primers: 5'-ACTCTGAACATGTTTATTCCC-3' and 5'-CTTAGACTAACCACGTTGGC-3' (3 min. at 94°C followed by 30 sec. at 94°C, 30 sec. at 55°C and 40 sec. at 72°C for 40 cycles). The RT-PCR products were separated on 1% agarose gel and viewed under UV light. Intensity quantification was performed with ImageJ software (Macbiophotonics plugins).

Homology modeling of VGLUT3

A putative 3D structure of VGLUT3 was established based on the X-ray crystal structure of the glycerol-3-phosphate transporter (GlpT) from *Escherichia coli*, which is a distant ortholog of vesicular glutamate carriers (Almqvist et al., 2007). Secondary structures were predicted using the membrane protein topology prediction method TransMembrane prediction using Hidden Markov Models (TMHMM) and a Hidden Markov Model for Topology Prediction (HMMTOP) (Krogh et al., 2001; Tusnady and Simon, 2001). Sequence alignments were generated between human VGLUT3 (SWISS-PROT accession n°: Q8NDX2) and GlpT (P08194) using Clustal W (Thompson et al., 1994). Alignments were manually refined to avoid gaps in predicted (human VGLUT) and known (GlpT) secondary structure elements. VGLUT3 3D models were built from these alignments and from the crystallographic atomic coordinates of GlpT (PDB ID: 1PW4) using the automated comparative modeling tool MODELER 9.0 (Discovery Studio 4.1, Accelrys Software Inc.). A three-dimensional model of the VGLUT3-p.A211V mutant was generated using a Build mutant protocol (Feyfant et al., 2007). The mutant model was minimized using the Adopted Basis Newton-Raphson (NR) algorithm, with a maximum step of 500 and a “generalized Born with Implicit Membrane

(GBIM)" as an implicit solvent model. A 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) membrane of 100 x 80 angstroms was added using software from Visual Molecular Dynamic (VMD 1.9.2, <http://www.ks.uiuc.edu/Research/vmd/vmd-1.9.2/>). Proteins were solvated, and ions were added using the solvation and ionization package from VMD1.9.2. The structure was minimized using a Adopted Basis Newton-Raphson (NR) algorithm, with a maximum step of 500 and an implicit solvent model. The system was then equilibrated using a short Nanoscale Molecular Dynamic software program (NAMD) of 1 ns.

Statistics

All statistical comparisons were performed with Prism 5 (GraphPad software Inc.). Each statistical test was appropriately chosen for the relevant experimental design. To compare two groups, a non-parametric Mann-Whitney U test was performed. One-way ANOVA, Kruskal-Wallis test or repeated-measures ANOVA was used for multiple group comparisons. All results are expressed as the mean \pm SEM. Differences were considered significant at $p < 0.05$.

RESULTS

The VGLUT3-p.A211V mutation reduces the expression level of VGLUT3 *in vitro*

To compare the expression of native VGLUT3 and VGLUT3-p.A211V, both alleles were expressed in cultures of stably transfected BON cells or hippocampal neurons. The transcripts coding for both isoforms were expressed at similar levels in BON cells when detected by RT-PCR (Fig. 2A; Mann-Whitney U test, $p > 0.05$, $n = 6$). In contrast, VGLUT3-p.A211V protein levels were markedly reduced relative to the WT isoform when measured by western blotting in BON cells (Fig. 2B; -64%, Mann-Whitney U test, $p = 0.0079$, $n = 5$) or in hippocampal neuronal cultures (Fig. 2C; -66%, Mann-Whitney U test, $p = 0.028$, $n = 4$). This decrease was also confirmed by immunofluorescence detection of VGLUT3 and VGLUT3-p.A211V in BON cells (Fig. 2D; G, H; -79%, Mann-Whitney U test, $p = 0.028$, $n = 4$) or in hippocampal neuronal cultures (Fig. 2E, I, J; -86%, Mann-Whitney U test, $p = 0.008$, $n = 5$). The same point mutation was then introduced into the coding sequence of VGLUT1 (VGLUT1-p.A198V). Interestingly, VGLUT1-p.A198V expression was dramatically reduced in BON cells (Fig. 2F, K, L; -90%, Mann-Whitney U test, $p = 0.005$, $n = 6$). Therefore, exchanging the alanine of the KWAPPLER motif for a valine was sufficient to markedly reduce the expression of vesicular glutamate transporters.

We then assessed whether VGLUT3-p.A211V was expressed in synaptic boutons in neuronal hippocampal cultures. Both VGLUT3 and VGLUT3-p.A211V were expressed in punctiform structures apposed to MAP2-positive dendritic processes (Fig. 2M and N). These VGLUT3- and VGLUT3-p.A211V-positive puncta co-localized with presynaptic markers, such as bassoon, and were apposed to PSD95-positive elements (Fig. 2O-R). Thus, the p.A211V mutation does not qualitatively alter the targeting of VGLUT3 to synaptic boutons.

Glutamate vesicular uptake and release are minimally altered by the p.A211V mutation

We then wondered whether p.A211V altered the 3D structure of VGLUT3. Theoretical models (Fig. 3A-H) were obtained using the crystal structure of the Glycerol-3-Phosphate Transporter (GlpT) from *E. coli* (PDB ID: 1PW4, 19% identity, 39% similarity with VGLUT3) as a template (Almqvist et al., 2007). As shown in Fig. 3, in these putative 3D models, alanine 211 is strategically located on a small cytoplasmic loop (cytoplasmic loop 4, CL4) and at the top of the transporter pore. Switching a valine for an alanine in this position only minimally modified the 3D structure of the loop. In particular, in the WT isoform, A211 interacted with the N-terminal domain through cysteine 67 hydrophobic binding (Fig. 3C, D), as well as with leucine 214 in CL4. These interactions were potentially altered with the p.A211V mutation (Fig. 3G, H). Both WT and mutant isoforms conserved a short distance interaction pattern with CL4 (K209; W210; P212; P213; L214 and E215). However in the N-terminal domain of the mutant, the interaction of A211 with C67 was abolished. In parallel, A211 from WT isoform interacted with T289 of the Cytoplasmic loop 6. This interaction was lost in the VGLUT3 p.A211V mutated isoform but was partially compensated by interactions with residues of CL6: H276 and I287 (Fig. 3H).

The putative 3D model suggests also that the alanine residue of the WT and the valine residue of VGLUT3-p.A211V faced the pore and hence could affect the entry of glutamate into the lumen of synaptic vesicles. Therefore, [³H]L-glutamate accumulation was measured in vesicular fractions from BON cells stably expressing VGLUT3 or VGLUT3-p.A211V. A small but non-significant reduction in vesicular glutamate uptake was observed with the VGLUT3-p.A211V isoform (Fig. 3I, Mann-Whitney U test, $p > 0.05$, $n = 10$). Hence, despite a 60-80% reduction in expression, the mutated VGLUT3 appeared to be as efficient as the WT allele at translocating glutamate into vesicles.

The capacity for glutamate release from neurons expressing the VGLUT3-p.A211V isoform was then evaluated by electrophysiological recordings. Autaptic hippocampal cultured neurons obtained from newborn VGLUT1^{-/-} mice were rescued by lentiviral-driven expression of either VGLUT3 (WT, black bars) or VGLUT3-p.A211V (red bars). Uninfected

neurons are shown with green bars. In these experiments, in order to determine the intrinsic properties of the VGLUT3-p.A211V isoform, expression levels of the mutant were purposely raised to equal WT. After two weeks in culture, synaptic responses were evoked by 2 ms depolarization of the cell at 0 mV. This resulted in an unclamped action potential and release of glutamate, which in turn generated EPSCs. The mean normalized EPSC peak amplitude was not different between the WT ($n = 72$) and the VGLUT3-p.A211V ($n = 73$) neurons (Fig. 3J). This was in contrast to the EPSC responses from VGLUT1^{-/-} neurons, which showed a severe reduction in synaptic response, demonstrating that the WT and the VGLUT3-p.A211V mutant rescued responses equally. We, next determined the readily releasable pool (RRP) size of VGLUT3, VGLUT3-p.A211V and VGLUT1^{-/-} neurons by applying hypertonic sucrose (500 mM for 5 s; (Rosenmund and Stevens, 1996)). The charge in VGLUT1^{-/-} neurons was reduced by 80%, as expected (Fig. 3K, $n = 73$, $p < 0.01$, (Wojcik et al., 2004)). VGLUT3 and VGLUT3-p.A211V neurons had a similar RRP charge (Fig. 3K). The expression levels of WT and VGLUT3-p.A211V as determined by immunofluorescence were not different (Fig. 3L). Moreover, the facilitation of responses that were evoked in pairs of action potential stimulation (25 ms interval, Fig. 3M) and the vesicular release probability were not different between VGLUT3 ($n = 72$) and VGLUT3-p.A211V ($n = 73$) neurons (Fig. 3M). The release probability in the VGLUT1^{-/-} neurons was reduced, as expected (Wojcik et al., 2004; Herman et al., 2014).

Analysis of spontaneous release activity (trace sample in Fig. 3O) demonstrated that mean mEPSC amplitude was slightly reduced in VGLUT3-p.A211V neurons compared with WT neurons (Fig. 3P and Q; WT, $n = 62$; VGLUT3-p.A211V, $n = 67$; $p < 0.005$). The mean frequency of mEPSCs was significantly different among all three groups (Fig. 3R). In VGLUT1^{-/-} neurons, mEPSC frequency was reduced by 80% (Fig. 3R; 1.8 Hz, $n = 51$, $p < 0.0005$), a finding consistent with the reduced RRP size (Fig. 3K) and the results of a previous publication (Wojcik et al., 2004). In VGLUT3-p.A211V expressing hippocampal isolated neurons, mEPSC frequency was reduced by almost 30% (Fig. 3R; WT, 8.5 Hz, $n = 72$; VGLUT3-p.A211V, 6 Hz, $n = 77$, $p < 0.005$). The mEPSC charge was also slightly

decreased in VGLUT3-p.A211V neurons compared with WT neurons (Fig. 3S; WT, $n = 62$; VGLUT3-p.A211V, $n = 67$; $p < 0.005$). Together, the results suggested that the p.A211V mutation does not alter the quantity of glutamate release, the RRP size or the release probability. In contrast, small reduction in spontaneous release activity was observed.

The expression of VGLUT3-p.A224V is dramatically reduced in the terminals of the mouse CNS

The p.A211V mutation is responsible for DFNA25 progressive deafness (Ruel et al., 2008). To gain insight into the underlying mechanisms, we used newly generated mutant mice, in which the corresponding amino acid was mutated in the VGLUT3 mouse genome (VGLUT3^{A224V/A224V}, Fig. 1). The expression levels of VGLUT3 mRNA and protein were measured by *in situ* hybridization, immunautoradiography and western blotting at different ages (P10, 3, 6 and 12 months) in WT, heterozygous and homozygous mice (Fig. 4).

As shown in Fig. 4, the levels of VGLUT3 transcript were unaltered in the striatum, hippocampus and raphe area at all ages assessed. In contrast protein levels were markedly altered at various ages in the striatum, hippocampus and raphe of VGLUT3^{A224V/A224V} mice (Fig. 4 and Table II). In the striatum of VGLUT3^{A224V/A224V} mice, the level of the mutant protein, as measured by immunautoradiography, was reduced by 76 to 85% compared with that in WT mice at all ages (Fig. 4A-J and Table II; Mann Whitney U test for P10 and 12 months; Kruskal-Wallis test for 3 and 6 months; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). A similar decrease in protein levels was observed in the hippocampus, as well as the raphe nuclei, with 69-76% and 50-74% reductions measured in the respective tissues at the same time points. Hence, the mean decrease across age and brain areas in VGLUT3^{A224V/A224V} mice was 70.3% (SEM \pm 2.7, $n = 12$). Reduced VGLUT3-p.A224V levels were also measured in mice expressing only one copy of the mutated gene and one copy of the WT gene (3-and 6-month old heterozygous VGLUT3^{A224V/+} mice, Fig. 4 and Table II). In heterozygous mice, the mean decrease was 34% (SEM \pm 4.1, $n = 8$). These results were further confirmed by western blotting experiments performed in the cortex, striatum and

hippocampus in 3-month-old VGLUT3^{A224V/+} and VGLUT3^{A224V/A224V} mice (Fig. 4K-L and Table II; Kruskal-Wallis test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). In summary, VGLUT3 expression was globally reduced by 70% in the brains of VGLUT3^{A224V/A224V} mice of all ages. To obtain mice with only one copy of the VGLUT3-p.A224V isoform, we crossed heterozygous VGLUT3^{+/-} mice with heterozygous VGLUT3^{A224V/+} mice. As shown in Fig. 4E-F, the decrease in VGLUT3 expression was more pronounced in VGLUT3^{A224V/-} than in VGLUT3^{A224V/A224V} mice. In the striatum of 3-month-old VGLUT3^{A224V/-} mice, VGLUT3 expression was reduced by 84% (Mann-Whitney U test, $p = 0.012$ relative to WT, $n = 8$). Moreover, 88% of the protein was lost in the hippocampus (Mann-Whitney U test, $p = 0.012$ relative to WT, $n = 8$) and 71% was lost in the raphe nuclei (Mann Whitney U test, $p = 0.028$ relative to WT, $n = 4$). Therefore, mice with one copy of the VGLUT3-p.A224V isoform demonstrate a larger decrease in VGLUT3 expression than mice expressing 2 mutant copies.

Unlike VGLUT1 and VGLUT2, which are almost exclusively present in nerve endings, VGLUT3 is present in both terminals and neuronal cell bodies (Gras et al., 2002; Somogyi et al., 2004). We, therefore, studied the cellular and subcellular distribution of VGLUT3-p.A224V in these cellular compartments (Fig. 5). The expression of VGLUT3-p.A224V was dramatically reduced in terminals from the striatum or hippocampus (CA1) compared with WT levels (Fig. 5A, B, C, striatum: -69%, Mann-Whitney U test, $p < 0.0001$, $n = 19$; Fig. 5E, F, G, hippocampus: -72%, Mann-Whitney U test, $p < 0.0001$, $n = 20$; 8 animals per genotype). However, surprisingly, VGLUT3 levels were similar in the soma of tonically active cholinergic interneurons (TANs) and the hippocampal basket cells from WT and VGLUT3^{A224V/A224V} mice (Fig. 5D, H, Mann-Whitney U test, $p > 0.05$). Furthermore, using electron microscopy, we observed that in TANs, the WT as well as the VGLUT3-p.A224V isoforms were distributed over similar subcellular organelles, including the endoplasmic reticulum (Fig. 5I, J; $n = 5$ for each genotype). Together, these data suggest that the VGLUT3-p.A224V isoform is not abnormally accumulated in the soma of neurons and that its expression is markedly reduced in terminals.

The mobility of VGLUT3-p.A211V is minimally modified

The aforementioned results suggested that VGLUT3-p.A211V was either not properly trafficked or was degraded in the nerve endings. To test the first hypothesis, we used fluorescence recovery after photobleaching (FRAP) to assess the mobility of VGLUT3 WT or VGLUT3-p.A211V in synaptic boutons, as previously described (Herzog et al., 2011). Hippocampal neurons were transduced at 2 DIV with a lentiviral vector expressing either the WT isoform of VGLUT3 or VGLUT3-p.A211V; both were tagged with the YFP derivative venus (Fig. 6A). VGLUT3-p.A211V transduction was adjusted to match the expression level of WT VGLUT3. Transduction of both isoforms yielded a punctate distribution of venus fluorescence that was reminiscent of presynaptic localization. A bleaching light pulse was applied to regions of interest (ROI) surrounding individual boutons in mature neurons after 17 days in culture (Fig. 6A). The exchange of bleached synaptic vesicles (SVs) and fluorescently labeled SVs from neurites surrounding the ROI was monitored during the next 75 minutes (Fig. 6A). VGLUT3-p.A211V fluorescence recovered to levels similar to those of the wild-type protein (Fig. 6A, B). An additional FRAP experiment with faster imaging rates in the first five minutes was performed to reveal possible differences in the initial recovery phase (Fig. 6B, fast FRAP inset). The kinetics of recovery seemed slightly different, but these differences were not statistically significant. However, the amplitude of recovery at 1 hour was similar for the mutant and wild-type experiments (Fig. 6C, Mann Whitney U test, $p = 0.1129$). Therefore, although we cannot rule out that the mobility of the over-expressed venus-tagged VGLUT3-p.A211V mutant isoform was altered, we conclude that the p.A211V mutation powerfully reduces VGLUT3 expression in terminals without apparently altering its mobility. .

The p.A224V mutation does not alter the behavior of mutant mice

Mice lacking VGLUT3 (VGLUT3^{-/-}) demonstrate increased anxiety behavior, as well as augmented basal and cocaine-induced locomotor activity (Gras et al., 2008; Amilhon et al., 2010; Sakae et al., 2015). We thus decided to characterize these behaviors in adult (3-4-

month-old) male VGLUT3^{A224V/A224V} mice with only 30% VGLUT3 expression. We first assessed the anxiety levels of WT and mutant animals in an open field and an elevated plus maze (Fig. 7A, B). Spontaneous as well as cocaine-induced locomotor activities were also measured (Fig. 7C, D). No significant differences between WT and VGLUT3^{A224V/A224V} mice were observed in any paradigm. Therefore, the p.A211V mutation does not modify VGLUT3-dependent mood or locomotor phenotypes.

We next investigated the behavior of VGLUT3^{A224V/-} mice that displayed a 78% reduction of VGLUT3 expression. We first compared the anxiety behaviors of WT and VGLUT3^{A224V/-} mice in the open field and elevated plus maze and found no differences (Fig. 7E, F). We then inspected basal and cocaine-induced locomotor activity of WT and VGLUT3^{A224V/-} mice (Fig. 7G, H). During the first two hours, we recorded the basal locomotor activity of mutant and WT mice and observed a significant increase in the activity in VGLUT3^{A224V/-} mice (Fig. 7G, repeated-measures ANOVA, $F_{(1, 29)}=1.472$, $p < 0.05$; H, cumulative analysis, +41%, Mann-Whitney U test, $p = 0.0329$). In contrast, the locomotor activity levels after cocaine injection were similar in both genotypes (Fig. 7H, Mann-Whitney U test, $p > 0.05$). Therefore, with only one copy of the VGLUT3-p.A224V isoform, and only 20% VGLUT3 expression, we detected minimal alterations in mutant mice behavior.

The p.A224V point mutation does not modify VGLUT3-dependent vesicular synergy over cortical [³H]5-HT accumulation

We then investigated whether the p.A224V mutation was able to alter the vesicular accumulation of glutamate in brain SVs of VGLUT3 mutants. VGLUT3 is a minor subtype compared with VGLUT1 and VGLUT2. It is therefore not possible to directly assess VGLUT3 activity in brain tissue. However, it has been previously established that VGLUT3 accelerates 5-HT accumulation in cortical synaptic vesicles through a molecular process called vesicular synergy (Amilhon et al., 2010; El Mestikawy et al., 2011). To estimate VGLUT3 activity in cortical synaptic vesicles, reserpine-sensitive vesicular uptake of [³H]5-HT was measured in the presence (+) or absence (-) of L-glutamate (Fig. 8). Similarly to previously reported

results (Amilhon et al., 2010), L-glutamate (10 mM) increased [^3H]5-HT reserpine-sensitive accumulation by 27% (Fig. 8, Mann-Whitney U test, $p < 0.0001$, $n = 26$) in the cortical synaptic vesicles of WT mice but had no effect on those of VGLUT3^{-/-} mice. Similarly to the results for WT mice, we observed a vesicular synergy in 5-HT vesicular uptake of +27% in VGLUT3^{A224V/+} mice (Mann-Whitney U test, $p = 0.0014$, $n = 7$), +22% in VGLUT3^{A224V/A224V} mice (Mann-Whitney U test, $p < 0.0001$, $n = 19$) and +22% in VGLUT3^{A224V/-} mice (Mann-Whitney U test, $p < 0.001$, $n = 19$). The stimulatory effect of glutamate on 5-HT cortical vesicular uptake was not significantly different between the WT and the three other genotypes (one-way ANOVA, $p > 0.05$). We conclude from these experiments that VGLUT3 activity was probably unaltered, even in mice with only 20-30% transporter expression.

High resolution fluorescence microscopy suggests that the p.A224V mutation alters the number of VGLUT3-positive vesicles

The aforementioned results strongly suggested that the p.A224V mutation markedly reduces the number of copies of VGLUT3 in synaptic boutons. This decrease in copy number may result in i) a reduction in the number of copies of the transporter on each vesicle or/and ii) a reduction in the number of VGLUT3-positive vesicles in each terminal. In an attempt to gain further insight in this issue, we used STED super resolution imaging of VGLUT3 in the striatum of mutant mice (Fig. 9).

STED microscopic observations after immunodetection showed spotty labeling of VGLUT3 and synaptophysin (Fig. 9A-E). The number of VGLUT3-positive puncta was highest in WT mice, was virtually nonexistent in VGLUT3^{-/-} mice and was decreased in VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice. The quantification of VGLUT3 immunopositive puncta revealed decreases of: 45% (Kruskal-Wallis test, $p = 0.0029$), 75% (Kruskal-Wallis test, $p = 0.0022$) and 84% (Kruskal-Wallis test, $p = 0.0022$) in VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice, respectively (Fig. 9F). These decreases were significantly correlated with the expression of VGLUT3 detected by immunoautoradiography (Fig. 9G, linear regression, $r^2 = 0.9528$, $p = 0.0044$). In contrast, the expression of synaptophysin was found to be similar in WT

693 and in the panel of VGLUT3 mutants (Fig. 9*F*). Interestingly, increasing laser power neither
694 increased the number of detected puncta (Fig. 9*H*, Kruskal-Wallis test, $p > 0.05$) nor allowed the
695 detection of a population of puncta with low intensity labeling.
696 Therefore, although it was not possible to determine whether the number of VGLUT3 copy
697 per vesicle was reduced, STED imaging suggested that diminishing the expression of
698 VGLUT3 reduced the number of VGLUT3-positive vesicles.
699

DISCUSSION

In two human families, a point mutation in the gene encoding VGLUT3 exchanges the amino acid alanine 211 for a valine and segregates with an early onset form of presbycusis (named DFNA25, (Ruel et al., 2008)). The VGLUT3-p.A211V (VGLUT3-p.A224V in rodent) point mutation is the first identified mutation of a VGLUT that is responsible for a human pathology. The impact of this mutation on the auditory system of the rodent is currently under investigation. Our preliminary results show that the p.A224V mutation recapitulates the human auditory pathology (Miot et al., manuscript in preparation). The aim of the present study was to determine whether and how the p.A211V mutation influences CNS activity. Consequently, functions of mutant VGLUT3 were investigated in cell cultures, as well as in a genetic mouse model.

Interestingly, alanine 211 is part of a peptide sequence (KWAPPLER) that is conserved among VGLUTs and is even present in the more distant transporter named sialin. According to a theoretical model (Fig. 3A-H), the KWAPPLER motif is part of a small cytoplasmic loop that faces the pore of the transporter. Both the conservation and the localization of alanine 211 argue for its functional importance. Structurally, our 3D model predicted that exchanging alanine for valine would have little influence on the structure of VGLUT3. In line with this conclusion, glutamate vesicular accumulation in BON cells and evoked EPSCs observed in isolated neuronal cultures expressing the VGLUT3-p.A211V isoform were not different from that observed with the WT isoform. Furthermore, indirect estimation of VGLUT3 activity in cortical synaptic vesicles provided evidence that the ability of VGLUT3 to load glutamate in vesicles was not different in the brains of WT or mutant mice.

However, in both cell cultures and in a mutant mouse model, the mutation had a dramatic effect on the expression of the transporter. The average decrease across investigated brain areas of the mutant transporter in VGLUT3^{A224V/A224V} mice was $70 \pm 2.7\%$. As expected, mice with a single copy of the mutated allele (VGLUT3^{A224V/-}) express $\approx 15\text{-}20\%$ of transporter whereas those with 2 copies (VGLUT3^{A224V/A224V}) express $\approx 20\text{-}30\%$ of transporter (Table II).

These decreases could impact more severely synapses expressing low levels of VGLUT3. It thus cannot be ruled out that the VGLUT3-p.A221V mutation could have stronger effects in some terminals present in non-inspected brain regions.

In the mutant mouse brain, the impact of the mutation on the expression of VGLUT3 appears to be constant between P10 and 12-month-old. This observation suggests that the reduction of VGLUT3 triggered by the mutation is independent from aging. Interestingly when the equivalent alanine in VGLUT1 (Alanine 198) was mutated into a valine residue, an even stronger decrease of the transporter was observed (-90%; Fig. 2F). Therefore, alanine in the KWAPPLER motif could be pivotal for the expression levels (or stability) of all VGLUTs.

In VGLUT3^{A224V/A224V} mice, the amount of the mutant transporter was dramatically reduced in hippocampal, striatal and cortical terminals. However, this point mutation had no effect on the mRNA or on protein levels in the soma and proximal dendrites of VGLUT3-positive neurons. This result implies that the mutation does not alter the transcription or translation of VGLUT3. Furthermore, the mobility of VGLUT3-p.A211V was not significantly modified in the axons. These results suggested that the mutant transporter could be less stable or more rapidly degraded in the terminals of neurons. However, it should be kept in mind that the expression of mutant VGLUT3 was as low in BON as in primary neurons or in the mouse brain. Further investigation of the half-life of the mutated isoform will be needed to clarify this issue.

We estimated the activity of the mutated isoform directly by measuring glutamate uptake in vesicles of BON cells and indirectly by measuring synaptic transmission in single neurons expressing the mutant transporter or by measuring vesicular synergy in cortical vesicles. In all cases, we found very minimal or no modifications of VGLUT3 activity.

A previous study reported that in *Caenorhabditis elegans*, 4 different point mutations of VACHT profoundly altered transporter activity (mostly the Km) without decreasing its expression or altering its targeting (Zhu et al., 2001). This illustrates the complex and diverse effects of point mutations on transporters activity.

Previous reports established that mice completely lacking VGLUT3 demonstrate increased anxiety and sensitivity to cocaine (Gras et al., 2008; Amilhon et al., 2010; Sakae et al., 2015).

Here, none of these phenotypes were observed with VGLUT3^{A224V/A224V} mice lacking more than 70% of VGLUT3, and only moderate effects were observed on locomotor activity in a mutant lacking up to 80% of VGLUT3 (VGLUT3^{A224V/-}). Our results showed that despite a substantial reduction in VGLUT3 expression, its biochemical and many integrated functions were unchanged. However, we cannot rule out that VGLUT3^{A224V/A224V} or VGLUT3^{A224V/+} mice may display some phenotypes that were not investigated in the present study. For example, mice lacking VGLUT3 demonstrate abnormal interictal discharges (Seal et al., 2008). These cortical generalized synchronous discharges are not accompanied by convulsive electrographic seizures. Interestingly, knock-out mice heterozygous for VGLUT3 (VGLUT3^{+/-}) also show sharp interictal spike discharges. We therefore cannot exclude the possibility that VGLUT3^{A224V/A224V} or VGLUT3^{A224V/+} mice present the abnormal interictal discharges reported in VGLUT3^{+/-} mice (Seal et al., 2008).

Nonetheless for phenotypes such as locomotor activity, sensitivity to cocaine or anxiety VGLUT3^{A224V/A224V} or VGLUT3^{A224V/+} mice demonstrated no behavioral alterations. As depicted in the model in Fig. 10A, there may be a substantial safety factor in the level of VGLUT3 required to sustain glutamate uptake such that only a small copy number is required to maintain these physiological functions. The threshold where a decrease of VGLUT3 level will start to impact its function is situated within a narrow range between 20 and 0% of wild-type level (Fig. 10A). Therefore, unlike those of the monoamine and acetylcholine vesicular transporters, VMAT2 and VACHT (Fon et al., 1997; Prado et al., 2006), the safety factor for VGLUT3 may be higher, with normal function being maintained, even with protein levels that are below 70% of WT levels.

A key question is whether these observations are also valid for VGLUT1 and VGLUT2. Whether vesicular accumulation of glutamate catalyzed by VGLUT1 or VGLUT2 is proportional to the amount of transporters has been a matter of debate (for review see (Schuske and Jorgensen, 2004) and (Freneau et al., 2004; Wojcik et al., 2004; Wilson et al., 2005)). Wojcik et al. have reported decreases in mEPSC amplitude and frequency in neurons lacking VGLUT1, and conversely, increased quantal size in neurons over-

expressing VGLUT1 (Wojcik et al., 2004). Furthermore, Wilson et al. reported that in hippocampal neuronal culture as well as during postnatal development, increasing the density of VGLUT1 results in enhanced glutamate release into the synaptic cleft (Wilson et al., 2005). These observations support a linear relationship between VGLUT1 amount and VGLUT1 activity (i.e. glutamate vesicular packaging). However, if glutamate vesicular loading and transmission were proportional to the copy number of VGLUTs, then heterozygous knockout mice (with 50% VGLUT expression) should display a 50% decrease in glutamatergic signaling, and this, in turn, should impact related behaviors. Fremeau et al. showed that VGLUT1^{+/-} heterozygous mice display normal excitatory transmission (Fremeau et al., 2004). In contrast, impaired mood regulation and memory have been reported in VGLUT1^{+/-} heterozygous mice (Tordera et al., 2007; Balschun et al., 2010). VGLUT2^{+/-} mice express only 50% of the WT level but demonstrate only discrete phenotypes in taste aversion, nociceptive responses and clonic seizures (Moechars et al., 2006; Leo et al., 2009; Schallier et al., 2009). However, these phenotypes are often modest.

Takamori and coworkers showed that, on average, synaptic vesicles contain 10 copies of VGLUT1 or 14 copies of VGLUT2 protein (Takamori et al., 2006). Hence, there are multiple copies of VGLUT1-2 inserted into vesicular membranes. The exact number of copies of VGLUT3 that are present on individual synaptic vesicles has not yet been determined. However, it can be reasonably assumed that, as with VGLUT1 and VGLUT2, multiple copies of VGLUT3 are inserted in the membrane of synaptic vesicles.

The redundancy of vesicular glutamate copies per vesicles could provide a safety factor in case of loss of transporters. For example, in *Drosophila*, reduced levels of DVGLUTs result in a reduction of mEPSC frequency, with no change in quantal size (Daniels et al., 2006). Additional studies support the notion that one copy of a VGLUT is sufficient to fill synaptic vesicles and to maintain a normal quantal size (Wojcik et al., 2004; Daniels et al., 2006; Schenck et al., 2009; Preobraschenski et al., 2014), as depicted in Model 1 (Fig 10A). Model 1 predicts that the decreased expression of VGLUT3-p.A224V could be due to a homogeneous reduction of the number of copies of transporter per vesicles. According to this

model, as long as there is at least 20% residual VGLUT3, the filling of vesicles with glutamate should be normal. The exact number of copies of VGLUT3 per vesicle corresponding to this percentage remains to be determined.

In the present study, we observed normal loading of [³H]L-glutamate into VGLUT3-p.A211V positive BON vesicles. However, a small significant decrease in mEPSC amplitude was observed in isolated neurons expressing the mutant isoform. It should be noted that electrophysiological recordings in autapses were obtained with increased amounts of mutant isoform with the objective of normalizing levels with those of the WT isoform. This represents a limitation of the present study as studying the effects of the mutation on synaptic activity without artificially increasing the level of the mutant transporter may have better represented the situation occurring in mutation carriers. Discrepancies between vesicular uptake and electrophysiological measurements can easily be explained by a difference in the sensitivity of both methods. In line with this explanation, a small but non-significant decrease was observed in vesicles of BON cells expressing VGLUT3-p.A211V. However, Model 1 does not explain why a significant decrease of mEPSC frequency was observed in isolated neurons expressing the mutant isoform. Furthermore, this model is not readily compatible with our observations obtained by STED microscopy. Surprisingly, STED showed a decrease of VGLUT3-positive fluorescent puncta per terminal. This suggests that the reduced expression of the mutated isoform in terminals is due to a reduction of the number of VGLUT3-positive vesicles as described by Model 2.

This second model is well in line with the decreased frequency of mEPSC observed in hippocampal autapses expressing VGLUT3-p.A211V. Indeed an increased number of “empty” vesicles could result in an increased number of silent events and therefore in a decreased frequency of mEPSCs. However, Model 2 is not compatible with the fact that vesicular uptake (in BON cells and in brain vesicles) and release probability (in hippocampal autapses) were virtually unchanged.

The discrepancy between the predictions of models 1 and 2 could be resolved if there is a non-homogeneous distribution of the mutant isoform between different pools of vesicles as

shown with Model 3. In this third putative model, we propose the existence of at least 3 populations of synaptic vesicles in VGLUT3^{A224V/A224V} mice. Synaptic vesicles could contain either high (or normal) or low level VGLUT3-p.A224V copies. Synaptic vesicles with a low copy number of mutant VGLUT3 would not be detected by STED microscopy. They could contain a slightly decreased amount of glutamate therefore explaining the small decrease in the amplitude of mEPSCs in hippocampal autapses. The vesicular populations with “high and low” VGLUT3-p.A211V content could allow a normal or only slightly altered quantum of glutamate. They also could explain why VGLUT3 biochemical, electrophysiological and behavioral function are preserved in VGLUT3^{A224V/A224V} mice. In addition a small fraction of synaptic vesicles are present with no copy of VGLUT3-p.A221V. These vesicles account for the decreased frequency of mEPSC depicted in Fig 3P and Q. If this model is correct, it implies that the KWAPPLER motif plays a central role in the vesicular targeting of VGLUT3. In particular, the trafficking of VGLUT3-p.A211V between different vesicular pools appears to be profoundly altered. Interestingly, synaptophysin labeling remained constant in the various VGLUT3 mutant mice analyzed in this study. This observation suggests that the number of synaptic vesicles is unaltered in the mutant mice.

The validation or invalidation of Model 3 will necessitate further experiments such as the use of super-resolution microscopic approaches (STORM or PALM). These methods that allow detection of single molecules may help to quantify the number of VGLUT3 per vesicle.

Rare variants of VGLUTs have begun to be identified in human pathologies (Ruel et al., 2008; Shen et al., 2010; Sakae et al., 2015). It is a key challenge to understand how these mutations can affect VGLUT functions and glutamatergic transmission. As shown here, the A224V mutation that causes deafness in humans profoundly alters the protein levels of VGLUT3, but minimally alters its functions. Our study reveals an unexpected redistribution of VGLUT3 in the synaptic vesicles of VGLUT3^{A224V/A224V} mice brain. Furthermore, we suggest the existence of a large safety factor in the number of VGLUT3 molecules required to sustain normal physiological functions. Further experiments will be required to validate or invalidate the three models proposed in Fig. 10. Clarifying this question will be important for gaining a

868 complete understanding of the pathologies that involve VGLUTs.

REFERENCES

- Almqvist J, Huang Y, Laaksonen A, Wang DN, Hovmoller S (2007) Docking and homology modeling explain inhibition of the human vesicular glutamate transporters. *Protein Sci* 16:1819-1829.
- Amilhon B, Lepicard E, Renoir T, Mongeau R, Popa D, Poirel O, Miot S, Gras C, Gardier AM, Gallego J, Hamon M, Lanfumey L, Gasnier B, Giros B, El Mestikawy S (2010) VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. *J Neurosci* 30:2198-2210.
- Balschun D, Moechars D, Callaerts-Vegh Z, Vermaercke B, Van Acker N, Andries L, D'Hooge R (2010) Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning. *Cereb Cortex* 20:684-693.
- Bellocchio EE, Reimer RJ, Freneau RT, Edwards RH (2000) Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. *Science* 289:957-960.
- Bernard V, Levey AI, Bloch B (1999) Regulation of the subcellular distribution of m4 muscarinic acetylcholine receptors in striatal neurons in vivo by the cholinergic environment: evidence for regulation of cell surface receptors by endogenous and exogenous stimulation. *J Neurosci* 19:10237-10249.
- Daniels RW, Miller BR, DiAntonio A (2011) Increased vesicular glutamate transporter expression causes excitotoxic neurodegeneration. *Neurobiol Dis* 41:415-420.
- Daniels RW, Collins CA, Chen K, Gelfand MV, Featherstone DE, DiAntonio A (2006) A single vesicular glutamate transporter is sufficient to fill a synaptic vesicle. *Neuron* 49:11-16.
- Daniels RW, Collins CA, Gelfand MV, Dant J, Brooks ES, Krantz DE, DiAntonio A (2004) Increased expression of the *Drosophila* vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. *J Neurosci* 24:10466-10474.
- De Gois S, Slama P, Pietrancosta N, Erdozain AM, Louis F, Bouvrais-Veret C, Daviet L, Giros B (2015) Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane. *J Biol Chem* 290:17848-17862.
- El Mestikawy S, Wallen-Mackenzie A, Fortin GM, Descarries L, Trudeau LE (2011) From glutamate co-release to vesicular synergy: vesicular glutamate transporters. *Nat Rev Neurosci* 12:204-216.
- Fasano C, Thibault D, Trudeau LE (2008) Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. *Curr Protoc Neurosci* Chapter 3:Unit 3 21.
- Feyfant E, Sali A, Fiser A (2007) Modeling mutations in protein structures. *Protein Sci* 16:2030-2041.

- 905 Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH (1997) Vesicular transport
 906 regulates monoamine storage and release but is not essential for amphetamine action.
 907 *Neuron* 19:1271-1283.
- 908 Fremeau RT, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellocchio EE, Fortin
 909 D, Storm-Mathisen J, Edwards RH (2001) The expression of vesicular glutamate transporters
 910 defines two classes of excitatory synapse. *Neuron* 31:247-260.
- 911 Fremeau RT, Burman J, Qureshi T, Tran CH, Proctor J, Johnson J, Zhang H, Sulzer D,
 912 Copenhagen DR, Storm-Mathisen J, Reimer RJ, Chaudhry FA, Edwards RH (2002) The
 913 identification of vesicular glutamate transporter 3 suggests novel modes of signaling by
 914 glutamate. *Proc Natl Acad Sci U S A* 99:14488-14493.
- 915 Fremeau RT, Jr., Kam K, Qureshi T, Johnson J, Copenhagen DR, Storm-Mathisen J,
 916 Chaudhry FA, Nicoll RA, Edwards RH (2004) Vesicular glutamate transporters 1 and 2 target
 917 to functionally distinct synaptic release sites. *Science* 304:1815-1819.
- 918 Gras C, Herzog E, Bellenchi GC, Bernard V, Ravassard P, Pohl M, Gasnier B, Giros B, El
 919 Mestikawy S (2002) A third vesicular glutamate transporter expressed by cholinergic and
 920 serotonergic neurons. *J Neurosci* 22:5442-5451.
- 921 Gras C, Amilhon B, Lepicard EM, Poirel O, Vinatier J, Herbin M, Dumas S, Tzavara ET,
 922 Wade MR, Nomikos GG, Hanoun N, Saurini F, Kemel ML, Gasnier B, Giros B, El Mestikawy
 923 S (2008) The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone.
 924 *Nat Neurosci* 11:292-300.
- 925 Herman MA, Ackermann F, Trimbuch T, Rosenmund C (2014) Vesicular glutamate
 926 transporter expression level affects synaptic vesicle release probability at hippocampal
 927 synapses in culture. *J Neurosci* 34:11781-11791.
- 928 Herzog E, Gilchrist J, Gras C, Muzerelle A, Ravassard P, Giros B, Gaspar P, El Mestikawy S
 929 (2004) Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain.
 930 *Neuroscience* 123:983-1002.
- 931 Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, Gasnier B, Giros B, El
 932 Mestikawy S (2001) The existence of a second vesicular glutamate transporter specifies
 933 subpopulations of glutamatergic neurons. *J Neurosci* 21:RC181.
- 934 Herzog E, Nadrigny F, Silm K, Biesemann C, Helling I, Bersot T, Steffens H, Schwartzmann
 935 R, Nöckerl UV, El Mestikawy S, Rhee J, Kirchhoff F, Brose N (2011) In vivo imaging of
 936 intersynaptic vesicle exchange using VGLUT1 Venus knock-in mice. *J Neurosci* 31:15544-
 937 15559.
- 938 Higley MJ, Gittis AH, Oldenburg IA, Balthasar N, Seal RP, Edwards RH, Lowell BB, Kreitzer
 939 AC, Sabatini BL (2011) Cholinergic interneurons mediate fast VGLUT3-dependent
 940 glutamatergic transmission in the striatum. *PLoS One* 6:e19155.

Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* 305:567-580.

Leo S, Moechars D, Callaerts-Vegh Z, D'Hooge R, Meert T (2009) Impairment of VGLUT2 but not VGLUT1 signaling reduces neuropathy-induced hypersensitivity. *Eur J Pain* 13:1008-1017.

McAnaney TB, Zeng W, Doe CF, Bhanji N, Wakelin S, Pearson DS, Abbyad P, Shi X, Boxer SG, Bagshaw CR (2005) Protonation, photobleaching, and photoactivation of yellow fluorescent protein (YFP 10C): a unifying mechanism. *Biochemistry* 44:5510-5524.

Moechars D, Weston MC, Leo S, Callaerts-Vegh Z, Goris I, Daneels G, Buist A, Cik M, van der Spek P, Kass S, Meert T, D'Hooge R, Rosenmund C, Hampson RM (2006) Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. *J Neurosci* 26:12055-12066.

Nelson AB, Bussert TG, Kreitzer AC, Seal RP (2014) Striatal cholinergic neurotransmission requires VGLUT3. *J Neurosci* 34:8772-8777.

Peirs C, Williams SP, Zhao X, Walsh CE, Gedeon JY, Cagle NE, Goldring AC, Hioki H, Liu Z, Marell PS, Seal RP (2015) Dorsal Horn Circuits for Persistent Mechanical Pain. *Neuron* 87:797-812.

Prado VF et al. (2006) Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. *Neuron* 51:601-612.

Preobraschenski J, Zander JF, Suzuki T, Ahnert-Hilger G, Jahn R (2014) Vesicular glutamate transporters use flexible anion and cation binding sites for efficient accumulation of neurotransmitter. *Neuron* 84:1287-1301.

Rosenmund C, Stevens CF (1996) Definition of the readily releasable pool of vesicles at hippocampal synapses. *Neuron* 16:1197-1207.

Ruel J, Emery S, Nouvian R, Bersot T, Amilhon B, Van Rybroek JM, Rebillard G, Lenoir M, Eybalin M, Delprat B, Sivakumaran TA, Giros B, El Mestikawy S, Moser T, Smith RJ, Lesperance MM, Puel JL (2008) Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. *Am J Hum Genet* 83:278-292.

Sakae DY et al. (2015) The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. *Mol Psychiatry*.

Schafer MK, Varoqui H, Defamie N, Weihe E, Erickson JD (2002) Molecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neurons. *J Biol Chem* 277:50734-50748.

- 976 Schallier A, Massie A, Loyens E, Moechars D, Drinkenburg W, Michotte Y, Smolders I (2009)
977 vGLUT2 heterozygous mice show more susceptibility to clonic seizures induced by
978 pentylenetetrazol. *Neurochem Int* 55:41-44.
- 979 Schenck S, Wojcik SM, Brose N, Takamori S (2009) A chloride conductance in VGLUT1
980 underlies maximal glutamate loading into synaptic vesicles. *Nat Neurosci* 12:156-162.
- 981 Schuske K, Jorgensen EM (2004) Neuroscience. Vesicular glutamate transporter--shooting
982 blanks. *Science* 304:1750-1752.
- 983 Seal RP, Wang X, Guan Y, Raja SN, Woodbury CJ, Basbaum AI, Edwards RH (2009) Injury-
984 induced mechanical hypersensitivity requires C-low threshold mechanoreceptors. *Nature*
985 462:651-655.
- 986 Seal RP, Akil O, Yi E, Weber CM, Grant L, Yoo J, Clause A, Kandler K, Noebels JL,
987 Glowatzki E, Lustig LR, Edwards RH (2008) Sensorineural deafness and seizures in mice
988 lacking vesicular glutamate transporter 3. *Neuron* 57:263-275.
- 989 Shen YC, Liao DL, Lu CL, Chen JY, Liou YJ, Chen TT, Chen CH (2010) Resequencing of
990 the vesicular glutamate transporter 2 gene (VGLUT2) reveals some rare genetic variants that
991 may increase the genetic burden in schizophrenia. *Schizophr Res* 121:179-186.
- 992 Siksou L, Silm K, Biesemann C, Nehring RB, Wojcik SM, Triller A, El Mestikawy S, Marty S,
993 Herzog E (2013) A role for vesicular glutamate transporter 1 in synaptic vesicle clustering
994 and mobility. *Eur J Neurosci* 37:1631-1642.
- 995 Somogyi J, Baude A, Omori Y, Shimizu H, El Mestikawy S, Fukaya M, Shigemoto R,
996 Watanabe M, Somogyi P (2004) GABAergic basket cells expressing cholecystokinin contain
997 vesicular glutamate transporter type 3 (VGLUT3) in their synaptic terminals in hippocampus
998 and isocortex of the rat. *Eur J Neurosci* 19:552-569.
- 999 Takamori S, Rhee JS, Rosenmund C, Jahn R (2000) Identification of a vesicular glutamate
1000 transporter that defines a glutamatergic phenotype in neurons. *Nature* 407:189-194.
- 1001 Takamori S, Rhee JS, Rosenmund C, Jahn R (2001) Identification of differentiation-
1002 associated brain-specific phosphate transporter as a second vesicular glutamate transporter
1003 (VGLUT2). *J Neurosci* 21:RC182.
- 1004 Takamori S, Malherbe P, Broger C, Jahn R (2002) Molecular cloning and functional
1005 characterization of human vesicular glutamate transporter 3. *EMBO Rep* 3:798-803.
- 1006 Takamori S et al. (2006) Molecular anatomy of a trafficking organelle. *Cell* 127:831-846.
- 1007 Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of
1008 progressive multiple sequence alignment through sequence weighting, position-specific gap
1009 penalties and weight matrix choice. *Nucleic Acids Res* 22:4673-4680.
- 1010 Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, Del Rio J (2007)
1011 Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with

reduced expression of the vesicular glutamate transporter 1 (VGLUT1). *Eur J Neurosci* 25:281-290.

Tusnady GE, Simon I (2001) The HMMTOP transmembrane topology prediction server. *Bioinformatics* 17:849-850.

Varga V, Losonczy A, Zemelman BV, Borhegyi Z, Nyiri G, Domonkos A, Hangya B, Holderith N, Magee JC, Freund TF (2009) Fast synaptic subcortical control of hippocampal circuits. *Science* 326:449-453.

Varoqui H, Schafer MK, Zhu H, Weihe E, Erickson JD (2002) Identification of the differentiation-associated Na⁺/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. *J Neurosci* 22:142-155.

Vigneault E, Poirel O, Riad M, Prud'homme J, Dumas S, Turecki G, Fasano C, Mechawar N, El Mestikawy S (2015) Distribution of vesicular glutamate transporters in the human brain. *Front Neuroanat* 9:23.

Weston MC, Nehring RB, Wojcik SM, Rosenmund C (2011) Interplay between VGLUT isoforms and endophilin A1 regulates neurotransmitter release and short-term plasticity. *Neuron* 69:1147-1159.

Wilson NR, Kang J, Hueske EV, Leung T, Varoqui H, Murnick JG, Erickson JD, Liu G (2005) Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. *J Neurosci* 25:6221-6234.

Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, Brose N, Rosenmund C (2004) An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. *Proc Natl Acad Sci U S A* 101:7158-7163.

Zander JF, Munster-Wandowski A, Brunk I, Pahner I, Gomez-Lira G, Heinemann U, Gutierrez R, Laube G, Ahnert-Hilger G (2010) Synaptic and vesicular coexistence of VGLUT and VGAT in selected excitatory and inhibitory synapses. *J Neurosci* 30:7634-7645.

Zhu H, Duerr JS, Varoqui H, McManus JR, Rand JB, Erickson JD (2001) Analysis of point mutants in the *Caenorhabditis elegans* vesicular acetylcholine transporter reveals domains involved in substrate translocation. *J Biol Chem* 276:41580-41587.

FIGURE LEGENDS

Figure 1. Alignment of VGLUT protein sequences and the VGLUT3^{A224V/A224V} mouse genomic construct. (A) Alignment of mouse (mVGLUT3) and human (hVGLUT3) VGLUT3 and mouse (mVGLUT1) VGLUT1 amino acid sequences. The three peptide sequences are highly conserved (black letters indicate residues conserved in the sequences, and blue letters indicate residues that are different). The KWAPPLER motif (red boxed text) is conserved in all three sequences. The mutated alanine residue is in red. This alanine is at positions 224, 211 and 198 in the mVGLUT3, hVGLUT3 and mVGLUT1 amino acid sequences, respectively. (B) Schematic representation of the targeting strategy. A targeting vector was constructed in which the GCG codon (encoding alanine 224) is replaced by a GTG codon in exon 5. A neomycin resistance selection cassette (flanked by two sites Lox, LoxP_Neo_LoxP) was integrated downstream of exon 5. An auto-excision of the selection cassette in a male chimera germ line provided a targeting allele with a valine at position 224 in exon 5 and a LoxP site used for genotyping. (C) Genotyping strategy of mouse VGLUT3 by PCR. Mice were genotyped with two primers (arrowheads P1, P2 in B) flanking each side of the LoxP site. PCR amplification of the wild-type (WT) allele (+) yielded a 219 bp band, and the mutated allele (A224V) yielded a 306 bp band in an agarose gel.

Figure 2. Expression of VGLUT3-p.A211V in cell cultures. (A) Gel image of RT-PCR products (negative image) showing no significantly difference between WT and VGLUT3-p.A211V transcript from BON cells stably expressing each allele. (B-C) Western blot (WB) quantification of VGLUT3 and VGLUT3-p.A211V in BON cell extracts (B) and in primary cultures of hippocampal neurons transfected with a VGLUT3 or VGLUT3-p.A211V expression plasmid (C). VGLUT3-p.A211V expression was reduced by 64% in BON cells (B) and by 66% in neurons (C). (D, E) Quantification of fluorescence intensity of WT and VGLUT3-p.A211V in stable BON cells (D) or in synaptic boutons in hippocampal neurons in culture (E). (F) Western blot detection and quantification of WT and VGLUT1-p.A198V in

BON cell extracts. (G, H) Immunofluorescence microphotographs of VGLUT3 (green) in BON cells stably transfected with a VGLUT3 (G) or VGLUT3-p.A211V (H) expression plasmid. (I, J) Hippocampal neurons transiently transfected with a VGLUT3 (I) or VGLUT3-p.A211V (J) expression plasmid. Nuclei were labeled with DAPI (blue). (K-L) Immunofluorescence of the WT isoform of VGLUT1 (K, red) or VGLUT1-p.A198V (L, red) in BON cell cultures that were transiently transfected with expression plasmid. (M-R) Co-localizations of VGLUT3 WT (M, O, Q, green) or VGLUT3-p.A211V (N, P, R, green) with MAP2 (M, N, red), bassoon (O, P, red) and PSD95 (Q, R, red) in primary hippocampal neuronal cultures transfected with a VGLUT3 or VGLUT3-p.A211V plasmid. Areas surrounded by a dashed line are enlarged in inserts. Scale bar in R: 5 μ m in G-L; 10 μ m in M-R; 1 μ m in insert of M-R.

Figure 3. Effect of the p.A211V mutation on 3D structure, glutamate vesicular accumulation and release. (A-H) Three- and two-dimensional model of human VGLUT3 (A-D) and VGLUT3-p.A211V (E-H) using crystallographic MFS transporter structures as a template. Packing of the helices viewed from the side (A, C, E, G) or the top (B, F). The alanine residue (in position 211) of VGLUT3 (A, B) and the valine residue of VGLUT3-p.A211V (E, F) that are exposed to the pore are shown in pink. Regions boxed in A and E are enlarged in C and G respectively. (D, H) Close up view and 2-dimensional interactions diagram of alanine 211 (D) or valine 211 (H). (I) Effect of the p.A211V mutation on H^+ ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) sensitive [3H]L-glutamate uptake by synaptic vesicles from BON cells stably expressing VGLUT3 (black bars) or VGLUT3-p.A211V (red bars). The small difference observed between the two populations of vesicles is not significant (NS). (J-R) Electrophysiological recordings of VGLUT1^{-/-} hippocampal autaptic neurons infected with lentivirus expressing VGLUT3 (WT) or VGLUT3-p.A211V isoforms. The number of recorded cells is indicated in bar graphs. Data are pooled from 2 independent cultures in M and from 4 independent cultures in J, K, L, N, O, P, Q and R. (J) Top: Representative traces of current responses after two unclamped action potentials with an interstimulus interval of 25 ms in VGLUT1^{-/-} autaptic neurons (green bars and traces)

expressing VGLUT3 (black bars and traces) or VGLUT3-p.A211V (red bars and traces). Artifacts and action potentials are blanked. Bottom: Plot of average EPSC amplitude size (first pulse) normalized to WT. (K) Left: Representative traces of current responses after application of sucrose (500 mM) for 5 s. Right: Plot of the average readily-releasable pool charge normalized to WT. (L) Comparison of the expression levels of WT and VGLUT3-p.A211V, determined by measuring immunofluorescence intensities and normalizing to the intensities of synaptic marker synaptophysin I (Syp1). (M) Plot of average paired-pulse ratios with an interstimulus interval of 25 ms. Data are pooled from 2 independent cultures. (N) Plot of average vesicular release probability. Data are pooled from 4 independent cultures. (O) Example of mEPSCs traces in autaptic neurons. Scattered points and bar graphs of average: mEPSC frequency (P), mEPSC amplitude (Q) and mEPSC charge (R). Data are pooled from 4 independent cultures.

Figure 4. Regional expression of VGLUT3, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} in the central nervous system of mice at different ages. (A-J) Detection and quantification of VGLUT3, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V}, VGLUT3^{A224V/-} mRNA and protein expression by *in situ* hybridization or immunohistochemistry on coronal mouse brain sections taken at post-natal day 10 (P10, A and B) and the ages of 3 months (C-F), 6 months (G, H) or 12 months (I, J) in the striatum (Str), hippocampus (Hi), and dorsal and median raphe, (DR and MR, respectively). WT, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} mice expressed a similar level of transcripts (first column, B, D, H, J; Mann-Whitney U test for B, J; Kruskal-Wallis test for D, H,; $p > 0.05$, $n = 8$). (B, D, H second column and F) Loss of the protein in all areas from P10 until 1 year in VGLUT3^{A224V/A224V} mice ($n = 8$ for each genotype, Mann-Whitney U test or Kruskal-Wallis test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). In VGLUT3^{A224V/+} mice, there is a 34% decrease in VGLUT3 in all areas at 3 and 6 months (D, H). (E, F) In this experiment, the protein expression of VGLUT3 was compared in WT, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice ($n = 8$) in the striatum, hippocampus and dorsal raphe. VGLUT3 expression decreased by 70% in VGLUT3^{A224V/A224V} mice and further

decreased by 84% in VGLUT3^{A224V/-} mice in the striatum (Kruskal-Wallis test; in the striatum, WT vs VGLUT3^{A224V/+}, $p = 0.0043$; WT vs VGLUT3^{A224V/A224V}, $p = 0.0043$; WT vs VGLUT3^{A224V/-}, $p = 0.0012$. In the hippocampus, WT vs VGLUT3^{A224V/+}, $p = 0.01$; WT vs VGLUT3^{A224V/A224V}, $p = 0.0043$; WT vs VGLUT3^{A224V/-}, $p = 0.0012$. In raphe nuclei, WT vs VGLUT3^{A224V/+}, $p = 0.0571$; WT vs VGLUT3^{A224V/A224V}, $p = 0.0159$; WT vs VGLUT3^{A224V/-}, $p = 0.0286$). (K, L) Western blot detection (K) and quantification (L) of VGLUT3 in the cortex (Cx), striatum (Str) and hippocampus (Hi) of VGLUT3^{A224V/+} and VGLUT3^{A224V/A224V} mice at 3 months ($n = 5$; Kruskal-Wallis test; ** $p < 0.01$).

Figure 5. Expression of VGLUT3-p.A224V in soma and terminals of VGLUT3-positive neurons in the brain of WT and VGLUT3^{A224V/A224V} mice. (A-H) Immunofluorescence visualization and quantification of VGLUT3 in the striatum (A, C) and in the CA1 pyramidal field of the hippocampus (E, G) in WT (A, E) and VGLUT3^{A224V/A224V} mice (C, G). VGLUT3 expression is substantially reduced in terminals of the striatum (B, -69%) and hippocampus (F, -72%), whereas its expression is unchanged in the soma of TANs and basket cells (D, H). (I-J) Electron microphotographs of the soma of TANs in striatal sections of WT (I) and VGLUT3^{A224V/A224V} (J) mice. VGLUT3 is labeled with gold particles. The distribution of VGLUT3 labeling is similar in WT (I) and VGLUT3^{A224V/A224V} (J) mice. Abbreviations: er, endoplasmic reticulum; n, nucleus; or, stratum oriens of the hippocampus; py, stratum pyramidale of the hippocampus; rad, Stratum radiatum. Scale bar: 35 μm in A, C, E, G; 1 μm in I, J.

Figure 6. The p.A211V mutation does not alter VGLUT3 mobility. (A) Representative image sequence depicting the initial fluorescence in the chosen boutons (white arrow), the loss of fluorescence after bleaching (time point 02:10 min), and the gradual recovery of fluorescent material in the bleached region in hippocampal cultures expressing either VGLUT3-venus or VGLUT3-p.A211V-venus. (B) Kinetics of FRAP over 75 minutes in

neurons expressing VGLUT3-venus or VGLUT3-p.A211V-venus. Average recovery curves (error bars represent SEM) are shown in black for VGLUT3-venus and in red for VGLUT3-p.A211V-venus. Inset at top shows FRAP curves during the first 10 min, with images taken every 5 seconds. (C) Amplitude of recovery for VGLUT3-venus or VGLUT3-p.A211V-venus in bleached boutons 60 minutes after recovery from bleaching. Data are pooled from 5 independent cultures for FRAP and 3 independent cultures for Fast FRAP ($n = 25$ boutons per condition).

Figure 7. Behavioral analysis of VGLUT3^{A224V/A224V} mice. (A) In the open field, WT littermates, VGLUT3^{A224V/+} and VGLUT3^{A224V/A224V} mice spent the same time at the center of the open field (Kruskal-Wallis test, $p > 0.05$) and presented the same locomotor activity at the center and the periphery of the open field (Kruskal-Wallis test, $p > 0.05$). The number of animals is indicated in the bar graph. (B) Anxiety levels assessed in the elevated plus maze were similar in WT, VGLUT3^{A224V/+} and VGLUT3^{A224V/A224V} mice (Kruskal-Wallis test, $p > 0.05$). Horizontal exploration was measured for 6 min. No difference was found in total entries or in the time spent in open arms between the WT and the VGLUT3 mutant mice (Kruskal-Wallis test, $p > 0.05$). (C) Spontaneous locomotor activity of naive WT, VGLUT3^{A224V/+} and VGLUT3^{A224V/A224V} mice. Horizontal locomotor activity was recorded for five hours (first hour during the light cycle followed by four hours during the dark cycle). Spontaneous locomotor activity was similar in WT and mutant animals (Kruskal-Wallis test, $p > 0.05$). (D) Left: Time course of the locomotor effect of cocaine (10 mg/kg, ip) in WT ($n = 7$) and VGLUT3^{A224V/A224V} ($n = 6$) mice. Animals were placed in the cyclotron for 240 min for habituation and then injected with saline (NaCl 0.9%), placed back in the cyclotron for 60 min and then injected with cocaine (10 mg/kg). Following cocaine injection, locomotion was recorded for 95 min. There was no significant difference in locomotor activity between WT and mutant mice that were treated with cocaine (repeated-measures ANOVA, $p > 0.05$). Right: Cumulative horizontal locomotor activity over 60 min for saline (Sal)-treated or 95 min for cocaine-injected (Coc) WT ($n = 7$) and VGLUT3^{A224V/A224V} mice ($n = 6$). No difference was observed in

cumulative locomotor activity following saline or cocaine injection between the WT and the VGLUT3^{A224V/A224V} mice (Mann-Whitney U test, $p > 0.05$).

(E-H) Behavioral analysis of mice expressing only one copy of VGLUT3-pA224V (VGLUT3^{A224V/-}). (E) In the open field, WT and VGLUT3^{A224V/-} mice spent the same time in the center area and crossed the periphery or the central area the same number of times (Mann-Whitney U test, $p > 0.05$). (F) WT and VGLUT3^{A224V/-} mice presented the same anxiety level when assessed in the elevated plus maze (Mann Whitney U test, $p > 0.05$). (G) Time course of the locomotor effect of cocaine (10 mg/kg, ip) in WT mice and VGLUT3^{A224V/-} mice. Animals were placed in the cyclotron as described in (D). No significant differences in locomotor activity were observed after cocaine injection between the WT and the mutant mice (repeated-measures ANOVA, $p > 0.05$). (H) Cumulative horizontal locomotor activity during the first 120 min in the cyclotron or 60 min after saline injection (Sal) and 95 min after cocaine injection (Coc, 10 mg per Kg i.p) in WT ($n = 16$) and VGLUT3^{A224V/-} mice ($n = 15$). During the first two hours in the cyclotron, the locomotor activity of the VGLUT3^{A224V/-} mice was higher than the locomotor activity of the WT mice (Mann-Whitney U test, $p = 0.0329$). After saline injection, the VGLUT3^{A224V/-} mice were slightly hyperactive compared with the WT mice (Mann-Whitney U test, $p = 0.0270$). No difference was observed in cumulative locomotor activity following cocaine injection between the WT and the VGLUT3^{A224V/-} mice (Mann-Whitney U test, $p = 0.1725$).

Figure 8. The p.A224V mutation does not influence VGLUT3-dependent vesicular synergy. [³H]5-HT reserpine-sensitive uptake in cortical synaptic vesicles was measured in the presence (+) or absence (-) of L-glutamate (Glut). [³H]5-HT reserpine-sensitive vesicular accumulation was augmented by L-glutamate (10 mM) in the cortical synaptic vesicles of WT (+27%), VGLUT3^{A224V/+} (+27%), VGLUT3^{A224V/A224V} (+22%) and VGLUT3^{A224V/-} mice (+22%) but not in VGLUT3^{-/-} mice due to the absence of VGLUT3 from synaptic vesicles.

Figure 9. High-resolution fluorescence imaging by STED revealed a decrease in VGLUT3-positive vesicles in mutant mice. (A-E) Co-detection by STED microscopy of VGLUT3 (red) and synaptophysin (green) in axonal varicosities of the striatum of WT (A), VGLUT3^{A224V/+} (B), VGLUT3^{A224V/A224V} (C), VGLUT3^{A224V/-} (D) and VGLUT3^{-/-} (E) mice. VGLUT3 and Synaptophysin immunofluorescence events were observed as round shaped elements within striatal varicosities of WT, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice. In VGLUT3^{-/-} mice, only synaptophysin was detected. Note the decrease in the number of VGLUT3 immunopositive puncta in VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} mice compared with WT mice. (F) Quantification of VGLUT3 and synaptophysin immunofluorescent events per varicosities. The numbers of VGLUT3 immunopositive puncta were quantified in striatal axonal varicosities of WT, VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V}, VGLUT3^{A224V/-} and VGLUT3^{-/-} mice after double immunofluorescence (80, 76, 76, 90 and 105 varicosities per animal were quantified in 6 WT, 6 VGLUT3^{A224V/+}, 6 VGLUT3^{A224V/A224V}, 6 VGLUT3^{A224V/-} and 5 VGLUT3^{-/-} mice, respectively). Note that the number of VGLUT3 puncta decreased with the genotype. (G) Correlation between number of VGLUT3-positive puncta determined by STED and VGLUT3 expression determined by immunohistochemistry. The correlation was statistically significant (linear regression, $r^2 = 0.9528$; $p = 0.0044$). (H) Effect of laser power on the number of events of VGLUT3-fluorescence detection. The blue arrows indicate the laser power that was selected for the images shown in A-E. The number of puncta per varicosity did not differ significantly when the laser power increased (Kruskal-Wallis test, $p > 0.05$). Scale bar in E: 500 nm in A-E.

Figure 10. Putative models depicting the reduction in VGLUT3 at the synapses of different mouse genotypes. In this report, we investigated mouse models with variable levels of VGLUT3 expression: WT mice (two copies of WT VGLUT3 isoform; 100%), heterozygous mice (one copy of WT VGLUT3 isoform and one copy of VGLUT3-p.A224V allele; 67%), homozygous mice (two copies of the mutated VGLUT3-p.A224V allele; 28%), VGLUT3^{A224V/-} mice (expressing only one copy of the mutated VGLUT3-p.A224V allele; 21%),

and VGLUT3 knockout mice (no copy of VGLUT3; 0%). (A) The black curve shows the relationship between VGLUT3 expression (detected by immunautoradiography) and the activity of VGLUT3 (indirectly assessed by measuring vesicular synergy). VGLUT3 activity did not decline in proportion to the amount of VGLUT3 in the expression range between 100% and 21% (black curve). The absence of a correlation between these two sets of measurements explains the virtual lack of a VGLUT3-dependent phenotype in our panel of mutants. This model predicts that these phenotypes will be observed in the gray zone of the curve (red curve).

(B) Three putative models that may account for the reduction in VGLUT3 at the synapses are compared with our experimental results. In WT mice, numerous copies of VGLUT3 are uniformly distributed between synaptic vesicles, and these vesicles are “normally” loaded (100% gray level) with glutamate. In model 1 (molecular model), VGLUT3 copies are uniformly decreased in all vesicles of VGLUT3^{A224V/A224V} mice. In this model, the vesicular content of glutamate is minimally decreased in all vesicles. This decrease in glutamatergic quantal size cannot be observed with bulk methods, such as vesicular uptake or behavioral measurements, but can be detected by more sensitive electrophysiological techniques. Model 1 would be compatible with i) an absence of change in vesicular uptake (observed in BON cells) and vesicular synergy (VS, observed in cortical vesicles) and ii) a decrease in the amplitudes of the mEPSCs that were observed in recordings of isolated neurons. Model 2 (vesicular model) is based on the STED high-resolution inspection of VGLUT3-positive terminals in our panel of mutants. In this model, in a small proportion of vesicles, the number of VGLUT3-p.A224V copies per vesicles is similar (or minimally decreased) to that found in WT neurons. According to the electrophysiological recordings of autapses, these vesicles may contain normal levels of glutamate and be preferentially docked. The remaining vesicles (80%) will contain neither VGLUT3 nor glutamate. This model is consistent with the decreased frequency of the mEPSCs.

A mixed model (model 3) of these two models may better explain all of our experimental results. In this model, we found vesicles without VGLUT3, a small proportion of vesicles

1264 expressing the correct number of VGLUT3-p.A224V copies and a third population of vesicles
1265 in which the number of VGLUT3 copies were uniformly decreased in all vesicles of the
1266 synapses from VGLUT3^{A224V/A224V} mice.

1267

1268 **Table I. List of mutants mice used in the study**

Number of copies of VGLUT3 allele			
Name	VGLUT3 ⁺	VGLUT3 ^{A224V}	VGLUT3 ⁻
WT or VGLUT3^{+/+}	2	0	0
VGLUT3^{A224V/+}	1	1	0
VGLUT3^{A224V/A224V}	0	2	0
VGLUT3^{A224V/-}	0	1	1
VGLUT3^{-/-}	0	0	2

1269

1270

Table II. Percentage of decrease in VGLUT3 expression as determined by immunohistochemistry in the striatum, hippocampus and raphe nuclei of VGLUT3^{A224V/+}, VGLUT3^{A224V/A224V} and VGLUT3^{A224V/-} at 10 days postnatal (P10) and 3, 6 or 12 months of age (mo).

		Age	P10	3 mo	6 mo	12 mo
Brain area	Genotype	% VGLUT3 decrease				
Striatum	VGLUT3 ^{A224V/+}	N.A.	34	50	N.A.	
	VGLUT3 ^{A224V/A224V}	83	76	77	85	
	VGLUT3 ^{A224V/−}	N.A.	84	N.A.	N.A.	
Hippocampus	VGLUT3 ^{A224V/+}	N.A.	26	38	N.A.	
	VGLUT3 ^{A224V/A224V}	76	69	70	78	
	VGLUT3 ^{A224V/−}	N.A.	88	N.A.	N.A.	
Dorsal Raphe	VGLUT3 ^{A224V/+}	N.A.	16	24	N.A.	
	VGLUT3 ^{A224V/A224V}	50	46	61	77	
	VGLUT3 ^{A224V/−}	N.A.	71	N.A.	N.A.	
Median Raphe	VGLUT3 ^{A224V/+}	N.A.	20	29	N.A.	
	VGLUT3 ^{A224V/A224V}	N.A.	74	63	N.A.	


Table III. Percentage decrease in VGLUT3 expression as determined by western blot analysis of the cortex, striatum and hippocampus of heterozygous and homozygous VGLUT3-p.A224V expressing mice at 3 months of age (mo).

Brain area	Age 3 mo	
	Genotype	% VGLUT3 decrease
Cortex	VGLUT3 ^{A224V/+}	63
	VGLUT3 ^{A224V/A224V}	72
Striatum	VGLUT3 ^{A224V/+}	55
	VGLUT3 ^{A224V/A224V}	85
Hippocampus	VGLUT3 ^{A224V/+}	47
	VGLUT3 ^{A224V/A224V}	70

A

mVGLUT3 STLNM**F**IPSAARVHYGCV**MG**VRIQLQGLVEGVVTYPACHGM**WS**KW**A**PPLERSRLATT**S**FCGS 240
hVGLUT3 STLNM**F**IPSAARVHYGCV**MC**VRIQLQGLVEGVVTYPACHGM**WS**KW**A**PPLERSRLATT**S**FCGS 227
mVGLUT1 STLNM**L**IPSAARVHYGCV**IF**VRIQLQGLVEGVVTYPACHGI**W**SKW**A**PPLERSRLATT**A**FCGS 214

B



C




Figure 1 Ramet et al.




Figure 2 Ramet et al.




Figure 3 Ramet et al.




Figure 4 Ramet et al.




Figure 5 Ramet et al.






Figure 6 Ramet et al.




Figure 7 Ramet et al.




Figure 8 Ramet et al.





Figure 10 Ramet et al.